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bp  base pair 
CD4 cluster of differentiation 4, a glycoprotein expressed 
predominantly in helper T cells 
CD8 cluster of differentiation 8, a glycoprotein expressed 
predominantly in cytotoxic T cells 
C.I.  confidence interval 
cM  centimorgan 
DH  dermatitis herpetiformis 
ELISA  enzyme-linked immunosorbent assay 
EMA  endomysial antibody 
EMSA  electophoretic mobility shift assay 
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HLA  human leukocyte antigen 
HLA-DQ  a human leukocyte antigen heterodimer consisting of DQA1 and 
  DQB1 molecules 
IFN   interferon gamma 
IgA  immunoglobulin A 
IgG  immunoglobulin G 
IL  interleukin 
IL18R1  interleukin 18 receptor 1 
IL18RAP  interleukin 18 receptor accessory protein, interleukin 18 receptor 
  beta 
kb  kilobase 
kDa  kilodalton 
KLRK1  killer cell lectin-like receptor subfamily K, member 1 
LD  linkage disequilibrium 
LOD  logarithm of odds 
Mb  megabase 
MHC  major histocompatibility complex 
MICA  MHC class I polypeptide-related sequence A 
MYO9B  myosin IXB 
NPL  non-parametric linkage 
OR  odds ratio 
PBMC  peripheral blood mononuclear cell 
SNP  single-nucleotide polymorphism 
TDT  transmission-disequilibrium test 
TGM2  transglutaminase 2 (C polypeptide, protein-glutamine-gamma- 
  glutamyltransferase, tissue transglutaminase) 
Th1  T helper cell type 1: a subset of CD4+ T cells 
Th2  T helper cell type 2: a subset of CD4+ T cells 





Celiac disease, or gluten intolerance, is triggered by dietary glutens in genetically susceptible 
individuals and it affects approximately 1% of the Caucasian population. The best known 
genetic risk factors for celiac disease are HLA DQ2 and DQ8 heterodimers, which are 
necessary for the development of the disease. However, they alone are not sufficient for 
disease induction, other risk factors are required. This thesis investigated genetic factors for 
celiac disease, concentrating on susceptibility loci on chromosomes 5q31-q33, 19p13 and 
2q12 previously reported in genome-wide linkage and association studies. In addition, a novel 
genotyping method for the detection of HLA DQ2 and DQ8 coding haplotypes was validated.  
This study was conducted using Finnish and Hungarian family materials, and Finnish, 
Hungarian and Italian case-control materials. Genetic linkage and association were analysed 
in these materials using candidate gene and fine-mapping approaches.  
The results confirmed linkage to celiac disease on the chromosomal regions 5q31-q33 and 
19p13. Fine-mapping on chromosome 5q31-q33 revealed several modest associations in the 
region, and highlighted the need for further investigations to locate the causal risk variants. 
The MYO9B gene on chromosome 19p13 showed evidence for linkage and association 
particularly with dermatitis herpetiformis, the skin manifestation of celiac disease. This 
implies a potential difference in the genetic background of the intestinal and skin forms of the 
disease, although studies on larger samplesets are required.  
The IL18RAP locus on chromosome 2q12, shown to be associated with celiac disease in a 
previous genome-wide association study and a subsequent follow-up, showed association in 
the Hungarian population in this study. The expression of IL18RAP was further investigated 
in small  intestinal tissue and in peripheral  blood mononuclear cells.  The results showed that 
IL18RAP is  expressed  in  the  relevant  tissues.  Two  putative  isoforms  of  IL18RAP  were  
detected by Western blot analysis, and the results suggested that the ratios and total levels of 
these isoforms may contribute to the aetiology of celiac disease.  
A novel genotyping method for celiac disease-associated HLA haplotypes was also 
validated in this thesis. The method utilises single-nucleotide polymorphisms tagging these 
HLA haplotypes with high sensitivity and specificity. Our results suggest that this method is 
transferable between populations, and it is suitable for large-scale analysis.  
In conclusion, this doctorate study provides an insight into the roles of the 5q31-q33, 
MYO9B, IL18RAP and HLA loci in the susceptibility to celiac disease in the Finnish, 
Hungarian and Italian populations, highlighting the need for further studies at these genetic 





Together with other common immune-mediated diseases, such as type 1 diabetes, rheumatoid 
arthritis and asthma, celiac disease falls into the category complex diseases because it appears 
to be causally influenced by multiple risk factors. These factors can be genetic or 
environmental, or may be comprised of an interplay between both. Complex diseases can 
present with a variety of symptoms and disease manifestations, and they do not conform to 
the classical Mendelian inheritance patterns, although familial clustering can often be seen.  
As complex diseases affect a relatively large portion of the human population, and they 
are a major burden on health care systems, substantial resources are invested in understanding 
the aetiology of these diseases and developing better tools for disease diagnosis and 
individualised treatment. The challenge to research efforts is that the contribution of each risk 
factor to the disease is often very slight, and even the healthy population has varying degrees 
of predisposition in relation to the risk factors.  
Celiac disease also belongs to a group of inflammatory diseases with autoimmune 
features. Its unique feature is that the major environmental risk factor for celiac disease is 
known: the pathology is triggered by exposure to dietary gluten (Dicke 1950). Other 
environmental risk factors for celiac disease may also be involved. It is well recognised that 
certain haplotypes within the major histocompatibility complex (MHC) region constitute the 
main genetic risk factors for celiac disease (Sollid et al. 1989, Karell et al. 2003). Their role 
in the pathogenesis of the disease has also been confirmed (Molberg et  al. 1998), making 
celiac disease a relatively well-characterised disease when compared to several other 
disorders with complex aetiology. Nevertheless, our understanding of the genetic background 
and the pathogenesis of celiac disease remains incomplete, and is the focus of cutting-edge 
research. In particular, recent advances in the field of genetics have resulted in more powerful 
study designs to locate genetic risk factors for complex diseases such as celiac disease.  
In this thesis, genetic susceptibility loci for celiac disease were studied using Finnish, 
Hungarian and Italian patient materials. The study was started in 2005 after the main 
susceptibility loci for celiac disease were identified through genome-wide linkage scans. Two 
of the candidate loci were investigated in this study (I, II). Novel risk genes for celiac disease 
were highlighted in the first genome-wide association scan in celiac disease published in 2007 
and in its follow-up studies, and one of the newly identified genes was also analysed in this 
doctorate study (III). Lastly, a novel genotyping method to predict human leukocyte antigen 
(HLA) risk haplotypes for celiac disease was validated to be used in large scale research 
projects (IV). 
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Review of the literature 
1. Celiac disease 
Celiac disease (MIM #212750), also known as gluten intolerance, gluten sensitive 
enteropathy or celiac sprue, is a chronic inflammatory condition of the small intestinal 
mucosa with autoimmune features. It affects approximately 1% of the gluten-consuming 
population; although, similarly to atopic diseases and type 1 diabetes, the prevalence of celiac 
disease is increasing, and is already 2% in Finland (Lohi et al. 2007). Celiac disease is 
triggered by dietary glutens from wheat, barley and rye, which set off an inflammatory 
reaction in the small intestine, leading to villous atrophy and crypt hyperplasia. The villous 
atrophy classically leads to malabsorption of nutrients with various associated symptoms 
(Mäki and Collin 1997). Presently, the only cure for celiac disease is a strict gluten-free diet, 
which typically leads to a complete recovery of the small intestinal tissue.  
The pathogenesis of celiac disease remains incompletely understood, but the immune 
system - possibly with interplay between the adaptive and innate immune responses - has a 
major role. Several twin and family studies have shown that the genetic component of celiac 
disease is strong and is the main factor contributing to the disease susceptibility. To date, the 
only known functionally-characterised genetic risk factors for celiac disease are certain alleles 
in HLA genes located on chromosome 6p21.3. However, these variants do not explain the 
whole  genetic  background  of  celiac  disease,  and  there  is  evidence  for  several  genetic  non-
HLA risk variants. The search for other susceptibility genes is ongoing, and along with a 
growing understanding of the normal variation in the human genome, the puzzle of the 
complex genetic background to celiac disease is slowly starting to unravel.  
1.1. Clinical characteristics 
The clinical picture of celiac disease was first described by Samuel Gee in 1888 (Gee 1888), 
although the adverse effects of ingested gluten were recognised over 60 years later (Dicke 
1950). The various primary symptoms of celiac disease are caused by a flattening of the small 
intestinal mucosa, known as partial, subtotal or total villous atrophy (Figure 1). The villi are 
necessary for efficient absorption of ingested nutrients, and their absence leads to the classical 
symptoms of celiac disease, including diarrhoea, weight loss and fatigue. Severe 
malabsorption syndrome has also been common among patients affected with celiac disease. 
(Mäki and Collin 1997).  
The clinical picture of celiac disease has changed over time, and the clinical signs of celiac 
disease are becoming milder than the symptoms that have previously been defined as classical 
symptoms. Along with the increasing prevalence of celiac disease, so-called atypical 
symptoms and manifestations of celiac disease have become common and the disease can 
even be apparently symptom-free. There are several atypical symptoms associated with celiac 
disease, such as various neurological symptoms, dental enamel defects, infertility, 
osteoporosis, aphthosis of the mouth mucosa, joint symptoms and elevated liver-enzyme 
concentrations. As untreated celiac disease is associated with osteoporosis and severe 
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(although rare) conditions such as malignant lymphoma and neural ataxias, asymptomatic 
patients are also recommended to follow a gluten-free diet. (Mäki and Collin 1997). 
 
Figure 1 Healthy small intestinal mucosa (on the left) is characterised by long villi extending into 
the small intestinal lumen. Partial, subtotal or total villous atrophy is typical in celiac 
disease (on the right).  
1.1.1. Dermatitis herpetiformis 
Dermatitis herpetiformis (DH) (MIM 601230), the skin manifestation of celiac disease, 
affects approximately one-fourth of gluten intolerant patients (Collin and Reunala 2003). Its 
relationship with celiac disease was suggested by Samman in 1955 (Samman 1955) and 
established a decade later (Marks et al. 1966, Marks and Shuster 1968). DH is a blistering 
skin condition that can occur at any age (Reunala 2001). The majority of patients with DH are 
also affected with mostly asymptomatic intestinal manifestations of gluten intolerance 
(Gawkrodger et al. 1984, Savilahti et al. 1992). As with celiac disease, DH is cured by 
excluding gluten from the diet (Fry et al. 1973). Dapsone also efficiently controls the rash that 
is typical for DH (Reunala 2001). 
Like celiac disease, DH has a complex aetiology, and appears to share the same genetic 
background as the intestinal form of gluten intolerance. For example, the HLA alleles known 
to be associated with celiac disease also predispose to DH (Spurkland et al. 1997). DH and 
celiac disease also co-occur in the same families (Hervonen et al. 2002), indicating that these 
two distinct phenotypes are different manifestations of the same disease. Further evidence 
supporting this idea comes from monozygotic twins, where one individual of the genetically 
identical twin pair can have DH and the other has celiac disease (Hervonen et al. 2000). There 
is also evidence for changing phenotype from intestinal celiac disease to DH after long-term 
gluten exposure (Kurppa et al. 2008). In conflict with these studies, there is evidence for 
distinct genetic susceptibility factors underlying the two conditions (Holopainen et al. 2001). 
To date, it is not known what triggers DH rather than celiac disease. 
1.1.2. Refractory celiac disease 
Refractory celiac disease is a rare condition which can be defined as persisting or recurring 
villous atrophy and crypt hyperplasia with increased intraepithelial lymphocytes despite strict 
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gluten-free diet for at least 12 months. Refractory celiac disease can also manifest with severe 
persisting symptoms and require interventions independent of the duration of gluten-free diet. 
Refractory celiac disease has two categories. Patients with type I refractory celiac disease do 
not have aberrant T cells in their small intestinal epithelium and seem to profit from 
immunosuppressive treatment. Patients with type II refractory celiac disease demonstrate an 
aberrant clonal intraepithelial T cell population, and have a high risk of developing overt 
lymphoma. Type II refractory celiac disease is usually resistant to immunosuppressive 
therapies: cytotoxic chemotherapy and autologous stem cell transplantation have been 
suggested for treatment. (Al-Toma et al. 2007). 
1.1.3. Other associated disorders 
Celiac disease co-occurs with several other disease conditions. As expected, other 
autoimmune diseases associated with HLA DQ2 and DQ8 are more common among patients 
with celiac disease than the rest of the population. Among these conditions are type 1 
diabetes, autoimmune thyroid diseases, selective immunoglobulin A (IgA) deficiency, 
Sjögren’s syndrome, alopecia areata and Addison’s disease (Mäki and Collin 1997). Co-
morbidities of celiac disease with schizophrenia (Eaton et al. 2006) and rheumatoid arthritis 
(Neuhausen et al. 2008) have also been reported. 
1.2. Diagnostics 
The diagnostic criteria for celiac disease, established by the European Society for Paediatric 
Gastroenterology and Nutrition (ESPGAN), are small bowel mucosal atrophy with 
improvement or normalisation on a gluten-free diet, and the presence of circulating antibodies 
specific for celiac disease (Working group of European Society of Paediatric 
Gastroenterology  and  Nutrition  1990).  A  requirement  for  all  diagnostic  testing  of  celiac  
disease is that the patient is on a gluten-containing diet. Typically, the first step in diagnosis is 
a serologic test, where celiac disease-specific antibodies (IgA specific for tissue 
transglutaminase [TGM2] and IgA endomysial antibody [EMA]) are measured from the 
peripheral blood of the patients. For IgA-deficient patients a serological test based on 
immunoglobulin G (IgG) antibodies can be performed. Small intestinal villous patterns from 
the biopsy specimens are assessed based on Marsh and Oberhuber’s classification of duodenal 
histological lesions (Oberhuber et al. 1999).  
Diagnosis of DH is based on the demonstration of granular IgA deposits in sub-epidermal 
skin (van der Meer 1969). 
Traditionally, both positive serology and biopsy results are required for a presumptive 
diagnosis of celiac disease. However, as the clinical picture of celiac disease has been 
changing during the past years, gluten intolerance is no longer restricted only to villous 
atrophy. It is now recognised that individuals with normal mucosal villous structure can have 
celiac disease, with villous atrophy thought to develop gradually during the disease process 
(Mäki and Collin 1997). The question of whether the diagnostic criteria should be modified to 
be based less on the requirement of villous atrophy is subject to ongoing debate (Kaukinen et 
al. 2001, Kurppa et al. 2009). Given that celiac disease often presents with silent or atypical 
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symptoms, population screening for celiac disease using disease-specific autoantibodies has 
been suggested because early treatment of celiac disease may improve the quality of life for 
affected individuals (Viljamaa et al. 2005, Korponay-Szabó et al. 2007). 
1.3. Epidemiology 
The prevalence of celiac disease is around 1% in Western European populations, although 
there are differences between populations (Dube et al. 2005).  A  minority  of  the  affected  
individuals are symptomatic: the majority of patients demonstrate silent or latent celiac 
disease, which can be detected by antibody screening. Therefore, the prevalence of 
symptomatic patients presents only the tip of the so-called celiac disease iceberg (Mäki and 
Collin 1997).  
Like several other autoimmune and inflammatory diseases, the prevalence of celiac 
disease is increasing throughout the world. In Finland, the prevalence of both clinically 
diagnosed and previously unrecognised celiac disease has increased significantly during the 
past two decades. The total prevalence of celiac disease has recently been estimated to be 
already approximately 2% of the Finnish adult population; a two-fold increase compared to 
the prevalence 20 years earlier (Lohi et al. 2007). Such a rapid increase in prevalence may 
reflect changes in our environment and way of life.  
The hygiene hypothesis has been proposed to play a major role in the relatively recent 
increase in the prevalence of autoimmune and allergic diseases. This hypothesis argues that 
improvements to sanitation and health care, which lead to the reduction of microbial contacts 
and incidence of infectious diseases, have increased the prevalence of allergies and diseases 
with autoimmune-features (Bach 2002, Romagnani 2004, Sewell et al. 2002). There is some 
epidemiological evidence supporting the hygiene hypothesis in relation to celiac disease, but 
more detailed studies are still required to evaluate its role. For example, low economic status 
and inferior hygienic living conditions have been shown to protect from celiac disease in a 
study where prevalence rates were compared between Russian Karelia and Finland 
(Kondrashova et al. 2008). The two investigated populations share partly the same ancestry 
and are equally exposed to grains, but their socio-economic conditions differ significantly. 
Kondrashova et al. (2008) demonstrated that the prevalence of autoantibodies specific for 
celiac disease was significantly lower among study subjects from Russian Karelia than 
Finland (Kondrashova et al. 2008). Some epidemiological studies have also suggested that the 
season of birth for a child with celiac disease differs significantly from the pattern in the 
general population (Ivarsson et al. 2003, Lewy et  al. 2009). For example, Swedish children 
born in the summer had a higher risk of celiac disease when compared to children born in the 
winter (Ivarsson et al. 2003). This suggests that environmental risk factors with seasonal 
patterns, such as infections occurring most frequently in the winter, can play a role in celiac 
disease risk. It has also been observed that certain viral infections appear to increase the risk 
of celiac disease, such as adenovirus 12 and hepatitis C virus (Plot and Amital 2009). Thus, 
the  role  of  infections  and  microbial  contacts  in  the  aetiology  of  celiac  disease  still  requires  
further investigations.  
As with most autoimmune conditions, females are more frequently affected with celiac 
disease. Two-thirds of patients with celiac disease are females, implying that hormones may 
affect disease susceptibility.  
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Dietary patterns, especially in childhood, may affect disease incidence or age of onset. The 
amount and timing of gluten introduction in diet together with the duration of breast feeding 
was reported to have a dramatic effect on the appearance of celiac disease in Sweden 
(Ivarsson et al. 2000). The annual incidence of celiac disease in children younger than 2 years 
had increased four-fold in two years (1985-1987) followed by a sharp decline to the previous 
levels ten years later. This epidemic, rare for common complex diseases, coincided with 
changes in infant feeding practices. Introduction of dietary gluten to children at a later age, 
increases in the amount of gluten consumed, and reduced breastfeeding after dietary gluten 
introduction were suggested to increase the incidence of celiac disease (Ivarsson et al. 2000). 
2. Pathogenesis of celiac disease 
Celiac disease is predominantly a T lymphocyte-mediated disorder, with activation of both 
cellular and humoral immune responses in the small intestinal mucosa. Both adaptive and 
innate immune responses are seen in active celiac disease. These immunological reactions are 
triggered by dietary gluten from wheat, barley or rye, and they can lead to destruction of the 
small intestinal villous structure. The pathogenesis of celiac disease remains incompletely 
understood, but is thought to consist of several intersecting molecular and cellular events in 
the small intestine. The intestinal lesion is characterised by infiltration of lymphocytes to the 
epithelium, increased density of leukocytes in the lamina propria, crypt cell hyperplasia and 
villous atrophy (Trier 1991, Sollid 2000).  
2.1. Gluten as a triggering factor for celiac disease 
Gluten  is  composed  of  storage  proteins  from  the  endosperm  of  wheat,  barley  or  rye.  It  
comprises over 80% of the protein in a wheat seed, and is an important source of nutrition 
worldwide. Wheat gluten is composed of two types of proteins: alcohol-soluble gliadins and 
alcohol-insoluble glutenins. Gliadins comprise a family of proteins with a high content of 
glutamine and proline residues. They are phylogenetically related to secalins of rye and 
hordeins of barley, and they are all capable of triggering celiac disease in genetically 
susceptible individuals (Mäki and Collin 1997). Oats are distantly related to wheat, barley and 
rye; therefore, the structure of its storage proteins (avenins) differs from the structure of 
gliadins, secalins and hordeins. Avenins appear to be incapable of triggering pathology in 
most patients with celiac disease, although some concerns remain (Lundin et al. 2003, 
Peräaho et al. 2004, Arentz-Hansen et al. 2004, Holm et al. 2006).  
Due to their high content of proline and glutamine residues, gliadins, secalins and hordeins 
are relatively resistant to proteolytic digestion in the small intestine. This may explain the 
accumulation of large gliadin-derived polypeptides in the intestinal mucosa after gluten 
ingestion. Certain gliadin polypeptides have been observed to be more toxic than others for 
individuals with celiac disease: an immuno-dominant 33-mer gliadin peptide appears to be 
particularly good at stimulating T cell-mediated inflammatory responses seen in celiac small 
intestinal mucosa (Piper et al. 2002, Shan et al. 2002). Several other peptides have also been 
reported (Arentz-Hansen et al. 2002, Vader et al. 2002, Camarca et al. 2009). Other gliadin 
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epitopes are thought to be directly cytotoxic and have been shown to trigger innate immune 
responses (Giovannini et al. 2000, Hue et al. 2004, Barone et al. 2007). 
2.2. Tissue transglutaminase and its roles in celiac disease 
Tissue transglutaminase (TGM2) has been shown to be an important factor in the 
pathogenesis of celiac disease. It is a ubiquitously-expressed enzyme belonging to a family of 
calcium-dependent transamidating enzymes. It is usually active in the extracellular space and 
catalyses the covalent and irreversible cross-linking of a protein with a glutamine residue to a 
second protein with a lysine residue (Folk and Cole 1966, Folk and Chung 1985). With the 
formation of stable bonds between proteins, TGM2 is involved in stabilising tissue structures 
and is expressed at high levels during wound healing (Bowness et al. 1988) and angiogenesis 
(Haroon et al. 1999).  
Gliadin peptides are ideal substrates for TGM2 because of their high glutamine content. 
These peptides thereby act as glutamine donors for TGM2. The reaction between gliadin 
peptides and TGM2 creates a covalent link between the molecules, leading to gliadin-TGM2 
complexes (Szabolcs et al. 1987, Dieterich et al. 1997). Alternatively, in certain conditions, 
TGM2-catalysed deamidation of gliadins is favoured over cross-linking. When glutamine 
residues are deamidated they become negatively-charged glutamate residues. Deamidation is 
particularly favoured over protein cross-linking in low pH conditions. For example, the pH of 
the small intestine is slightly acidic, which may lead to TGM2 catalysing deamidation 
reactions (favourable for celiac disease) more frequently (Fleckenstein et al. 2002). 
Deamidated gliadin peptides bind to HLA DQ2 molecules with higher affinity than 
unmodified peptides (van de Wal et al. 1998, Arentz-Hansen et al. 2000), which may be 
extremely important in the pathogenesis of celiac disease. Higher affinity interactions would 
enable efficient presentation of gluten-derived peptides to the immune system, inducing the 
adaptive immune reactions observed in celiac disease (Lundin et al. 1993). On the other hand, 
cross-linking of TGM2 with gliadin peptides enables the presentation of this autoantigen as a 
hapten-carrier complex to the B cells of the immune system, putatively explaining the 
production of autoantibodies specific for celiac disease (Sollid et al. 1997) as described in 
chapter 2.4.2.  
2.3. Innate immunity and celiac disease 
Innate immunity constitutes the front line of defence against pathogenic agents. It is 
activated within minutes or hours after encountering the pathogen. Innate immunity does not 
rely on adaptive mechanisms or antigen-specific lymphocytes, allowing it to respond to threat 
immediately. The innate immune system is able to discriminate between self antigens and 
non-self antigens and it recognises a broad variety of pathogens. (Janeway et al. 2001).  
There is evidence that the innate immune system is involved in celiac disease. It is thought 
to be raised against gliadin peptides and it precedes and enables the initiation of adaptive 
immune responses (Maiuri et al. 2000). Gliadin peptides have been shown to induce rapid 
expression of interleukin (IL) 15 in duodenal biopsy samples from patients with untreated 
celiac disease (Maiuri et al. 2000, Mention et al. 2003). Hue et al. (2004) showed that the 
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toxic p31-49 gliadin peptide induces the expression of the non-classical HLA molecule MICA 
on the surface of enterocytes in active celiac disease. Gliadin peptides may induce innate 
immune responses through the increased expression of IL15 and upregulation of MICA by 
enterocytes. Expression levels of MICA have been found to correlate with the severity of the 
disease (Hue et al. 2004). 
MICA is known to be a ligand for the killer-cell lectin-like receptor subfamily K, member 
1 (KLRK1, NKG2D). KLRK1 is expressed by a subset of CD8+ T cells, T cells using a 
gamma-delta T cell receptor, and most natural killer cells (Bahram et al. 2005). Intraepithelial 
lymphocytes in the small intestine of patients with celiac disease also express KLRK1: such 
cells are capable of lysing epithelial cells through a KLRK1-MICA interaction (Hue et al. 
2004, Meresse et  al. 2004). Following these innate immune reactions, entry of gliadin 
peptides into the intestinal lamina propria is proposed to stimulate the action of the adaptive 
immune response.  
It has also been reported that gliadin increases enterocyte apoptosis (Giovannini et al. 
2000, Giovannini et al. 2003), suggesting a direct cytotoxic effect of gliadin that may 
contribute to the villous atrophy observed in celiac disease. However, contradictory effects of 
gliadin on intestinal enterocytes have been demonstrated, as gliadin has also been reported to 
rapidly induce actin rearrangements in intestinal epithelial cell lines and to enhance 
proliferation of epithelial cells (Barone et  al. 2007). These effects may lead to the 
maintenance of the typical atrophic and proliferative alterations of the small intestine in celiac 
disease.  
2.4. Adaptive immunity and celiac disease 
Adaptive immunity is characterised by high specificity to antigens, development of 
immunological memory and usually requires a few days to activate after encountering a novel 
antigen. Adaptive immunity is comprised of T cell-mediated immunity and humoral immunity 
(Janeway et al. 2001), both of which are activated in celiac disease.  
T cell-mediated immunity involves antigen presentation through HLA molecules by 
antigen presenting cells. The encounter between a naïve T cell and an antigen-HLA complex 
on antigen presenting cells stimulates T cells to become effector cells in the presence of 
sufficient co-stimulatory conditions. HLA class I molecules, expressed on virtually all 
nucleated cells, present intracellular pathogens to CD8+ T cells, which then differentiate and 
kill infected target cells. In contrast, HLA class II molecules are expressed almost exclusively 
on  antigen  presenting  cells,  such  as  dendritic  cells,  and  they  present  antigens  derived  from  
extracellular or intravesicular pathogens to CD4+ T cells. These CD4+ T cells can then 
differentiate into three types of effector T cells: T helper type 1 (Th1), T helper type 2 (Th2) 
or T helper type 17 (Th17) cells. (Janeway et al. 2001, Dardalhon et al. 2008).  
Th1, Th2 and Th17 cells activate different immune responses through the cytokines they 
produce. Th1 responses are characterised by the production of IL2, interferon-gamma (IFN ) 
and tumour necrosis factor beta (TNF ), and they are involved in activating CD8+ T cells and 
macrophages, and inducing B cells to produce IgG antibodies for opsonisation. Th2 responses 
are characterised by the production of IL4, IL5, IL13 and IL25, and they initiate the humoral 
immune response by activating naïve B cells to produce IgM antibodies followed by IgA, IgE, 
and IgG antibody isotypes. Th17 cells are a recently identified T helper cell population. These 
Review of the literature 
17 
cells are characterised by the production of IL17, IL22 and IL21, as well as the expression of 
the IL23 receptor. The immunological role of Th17 cells is not yet completely understood, but 
they appear to promote organ-specific inflammation. (Janeway et al. 2001, Dardalhon et al. 
2008).  
The normal consequence of activation of adaptive immune responses is clearance of a 
foreign antigen from the body. Although effector T cells have crucial roles in the elimination 
of infectious pathogens, they are also involved in certain disease conditions. Th2 cells are 
known to have a role in allergic reactions, whereas Th1 and also Th17 cells appear crucial in 
the induction and maintenance of chronic inflammatory processes such as autoimmunity. In 
autoimmune conditions, adaptive immune responses have developed against self antigens, a 
situation in which the immune system is incapable of eliminating the antigen. If these harmful 
immune responses are left unchecked, inflammatory injury to the body’s tissues may ensue. 
(Janeway et al. 2001, Dardalhon et al. 2008) 
Adaptive immune responses are active in celiac disease in the small intestinal mucosa. 
CD4+ T cell-mediated immune responses to gluten peptides have been demonstrated in 
patients, and the Th1 response appears to be particularly important for the disease pathology.  
2.4.1. HLA molecules and T cell stimulation by antigen presentation 
HLA  DQ2  and  DQ8  heterodimers  are  HLA  class  II  molecules  and  are  required  for  the  
development of celiac disease. These heterodimers consist of an alpha and a beta chain, which 
are encoded for by different genes, namely DQA1 and DQB1,  respectively.  The  pairing  of  
these chains creates an antigen binding groove. The antigen binding grooves of different HLA 
heterodimers can have different properties due to their differing amino acid compositions. 
HLA DQ2 and DQ8 heterodimers have a particularly high preference for negatively-charged 
amino acids, such as glutamic acid residues in deamidated gliadin peptides (van de Wal et al. 
1998, Arentz-Hansen et al. 2000). The DQ2 and DQ8 molecules mediate the immune 
responses triggered by dietary gluten. Stimulation with gliadin peptides leads to proliferation 
of T cells in biopsies from patients with DQ2 and DQ8 heterodimers (Lundin et  al. 1993, 
Lundin et al. 1994). Thus, gliadin peptides stimulate T cells through presentation by these DQ 
heterodimers.  
Recent evidence suggests that the preference for negatively-charged peptides by the DQ8 
heterodimer is not the only mechanism by which this molecule is involved in the pathogenesis 
of celiac disease. A certain positively-charged amino acid within the binding groove of the 
DQ8 heterodimer appears to promote the recruitment of T cell receptors with a negative 
charge at the complementary region during the response against native (not deamidated) 
gluten peptides presented by the DQ8 heterodimers (Hovhannisyan et al. 2008). This model 
provides an explanation of how the inflammatory responses are initiated in the mucosa of 
patients with celiac disease, although it is not yet known whether the DQ2 heterodimer has 
similar functions.  
The production of Th1 cytokines can lead to mucosal destruction and epithelial apoptosis 
in the small intestine. The cytokines produced by DQ2-restricted gliadin-specific T cell clones 
are dominated by IFN  (Nilsen et al. 1998), and the histological damage to mucosa in celiac 
disease appears to be mediated through cytokines, especially IFN -driven pathways 
(Przemioslo et al. 1995, Kontakou et  al. 1995b). However, IFN  activation on its own does 
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not  explain  the  intestinal  damage  seen  in  patients  with  celiac  disease,  as  IFN  can  also  be  
upregulated in treated patients without causing pathology (Forsberg et al. 2002). In addition 
to IFN , other cytokines show upregulation in an in vivo gluten challenge, such as tumour 
necrosis factor alpha (TNF ), IL2 and IL6 (Kontakou et  al. 1995a). IL18, which maintains 
Th1 responses by supporting IFN  production, is also expressed in samples from patients with 
celiac disease, but not in healthy controls (Salvati et al. 2002). Finally, there is emerging 
evidence about the role of Th17 cells in autoimmunity (Dardalhon et al. 2008), and the 
cytokines produced by these cells may play a role in the pathogenesis of celiac disease as well 
(Castellanos-Rubio et al. 2009).  
2.4.2. Antibodies in celiac disease 
Initiation of adaptive immune responses occurs when T cells are activated by signals from 
antigen presenting cells. Generally, B cells responsible for the antibody production require 
stimulatory signals from the effector T cells to be activated. When B cells are activated, they 
become antibody-secreting plasma cells, producing antibodies that can bind to antigens such 
as pathogens outside the cells. The antibodies can neutralise, opsonise or activate the 
complement system to eradicate the antigen. The effector functions of the antibody depend on 
its isotype. In autoimmune conditions, antibodies against self-antigens are often produced. 
(Janeway et al. 2001) 
Patients  with  celiac  disease  have  two  types  of  antibodies,  which  are  specific  for  the  
disease. They have antibodies against deamidated gliadin peptides (Ankelo et al. 2007, 
Kaukinen et al. 2007, Niveloni et al. 2007) and they also display autoantibodies of the IgA 
class against TGM2 (van de Wal et al. 1998). The anti-TGM2 antibody is proposed to be 
raised against TGM2 molecules within cross-linked TGM2-gliadin complexes. TGM2-
specific B cells are hypothesised to endocytose the TGM2-gliadin complexes. These 
molecules are then further processed in the B cells and presented to T cells via HLA class II 
molecules  on  the  B  cell.  The  presentation  of  gliadin  by  HLA  DQ2  molecules  activates  
gliadin-specific T cells, which then help TGM2-specific B cells to start antibody production 
(Sollid et al. 1997). Dietary gluten is thus responsible for the celiac disease-specific 
antibodies:  the  antibodies  disappear  when  gluten  is  excluded  from  the  diet  (Dieterich et  al. 
1997). 
The antibodies against TGM2 are produced in the small intestinal mucosa of patients with 
celiac disease (Marzari et al. 2001). These antibodies are present at the site of their production 
and also found circulating in the blood. In untreated patients with celiac disease, the anti-
TGM2 antibodies can also be found as deposits in the small intestinal mucosa on extracellular 
TGM2 below the epithelial layer and around blood vessels (Korponay-Szabó et al. 2004, 
Kaukinen et al. 2005). Even patients with early stage celiac disease who do not yet have 
villous atrophy have been shown to have these anti-TGM2 antibody deposits (Salmi et al. 
2006), often before detectable levels of serum antibodies are seen. 
It is still unclear whether the celiac disease-specific autoantibodies play a role in the 
pathogenesis of the disease. However, there is mounting support of this idea (Lindfors et al. 
2009). Celiac disease-specific IgA antibodies have been shown to disturb angiogenesis 
(Myrsky et al. 2008) and inhibit the differentiation of intestinal epithelial cells in vitro 
(Halttunen and Mäki 1999). A subset of anti-TGM2 IgA antibodies have also been reported to 
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be functionally active, increasing epithelial permeability in patients with untreated celiac 
disease (Smecuol et al. 1997, Zanoni et al. 2006). Furthermore, there is evidence that celiac 
disease specific autoantibodies are able to activate monocytes (Zanoni et al. 2006) and induce 
monocyte-mediated antibody-dependent cytotoxicity (Saalman et al. 1998). Thus, the 
activation of monocytes by the anti-TGM2 antibodies may participate in the pathogenesis of 
celiac disease.  
 
The adaptive and innate immune responses in celiac disease are summarised in Figure 2. 
 
 
Figure 2 A schematic picture of the innate (on the left) the adaptive (on the right) immune 
responses in celiac disease. Both responses are triggered by dietary gluten. In innate 
immune responses, gluten has direct cytotoxic effects on the enterocytes of the small 
intestinal epithelium. It also triggers the IL15, MICA and KLRK1 –mediated cell-lysis. 
The adaptive immune responses are driven by deamidated gluten peptides. TGM2 is 
responsible for the deamidation and is also able cross-link with gluten peptides. The 
deamidated gluten peptides are presented efficiently to the CD4+ T cells by HLA DQ2 
and DQ8 molecules. The activation of T cell-mediated immune responses leads to 
inflammation in the small intestine. The cross-linking of TGM2 with gluten enables the 
activation of TGM2-specific B cells and the production of anti-TGM2 antibodies. IEL: 
intraepithelial lymphocyte, APC: antigen presenting cell. 
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3. Genetics of celiac disease 
The mode of inheritance of celiac disease is not known, although there is strong evidence for 
genes playing an important role in the disease susceptibility. Family and twin studies can be 
used in estimating the proportion of genetic and environmental risk factors in the disease 
prevalence. The studies have shown that genetic components play a major role in the 
induction and manifestation of celiac disease. Depending on the study, the proband-wise 
concordance for celiac disease is 75-86% between monozygotic twins (Hervonen et al. 2000, 
Walker-Smith 1973, Bardella et al. 2000, Greco et al. 2002, Nistico et al. 2006), whereas the 
proband-wise concordance of celiac disease between dizygotic twins has been estimated to be 
16.7-20% (Greco et  al. 2002, Nistico et al. 2006). The difference in concordances between 
monozygotic twins and dizygotic twins provides an estimate of the size of the genetic 
component in celiac disease, which appears higher than in many other complex 
immunological disorders. For example, in type 1 diabetes the proband-wise concordance is 
23% for monozygotic twins and 5% for dizygotic twins (Kaprio et al. 1992). The concordance 
of celiac disease between ordinary siblings and dizygotic twins, both sharing approximately 
50% of their genes, is at the same level, indicating that a shared environment (apart from 
gluten ingestion) may only have a minor effect on the concordance in dizygotic twins (Greco 
et al. 2002, Bevan et al. 1999). According to Nistico et al. (2006), the heritability of celiac 
disease is up to 87%. 
Family studies have shown that the prevalence of celiac disease is 10% among first-degree 
relatives of gluten intolerant patients (Dube et al. 2005). The familiar clustering of celiac 
disease can be shown as a ratio of the prevalence of celiac disease between siblings of patients 
with celiac disease, and the population ( s). s is estimated to be 30-60 in celiac disease, 
further confirming the existence of a large genetic component in celiac disease (Risch 1987, 
Petronzelli et al. 1997). 
Certain common HLA alleles are known to be important genetic risk factors for celiac 
disease. Despite their crucial role in pathogenesis, their effect on the genetic susceptibility for 
celiac disease seems to be minor, indicating that other HLA-unlinked susceptibility genes for 
celiac disease exist (Bevan et al. 1999, Risch 1987, Petronzelli et al. 1997). HLA haplotype 
sharing studies in families have shown that the contribution of the HLA region to the 
development of celiac disease among siblings is less than 40% (Bevan et al. 1999, Petronzelli 
et al. 1997). These results indicate that the remaining genetic risk is likely to be conferred by 
non-HLA genes (Bevan et  al. 1999, Petronzelli et al. 1997). There is abundant evidence for 
several HLA-unlinked susceptibility genes for celiac disease, with each gene conferring only a 
minor effect on the disease risk.  
3.1. Molecular genetics 
The genetic information of humans is stored in the cell nuclei in 23 chromosome pairs and 
also within the mitochondria. The genetic information is composed of deoxyribonucleic acid 
(DNA), which is an antiparallel double-helical macromolecule consisting of pairs of 4 
nucleotides (adenine [A], cytosine [C], guanine [G], and thymine [T]) forming an organised 
linear sequence (Strachan and Read 2004). DNA contains the genetic instructions that are 
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used in the development and function of cells and organisms. Differences between individuals 
are largely due to different types of genetic polymorphisms, i.e. differences in the DNA. Most 
of  these  polymorphisms  are  part  of  normal  genetic  variation,  whereas  some  of  them  are  
known to directly cause diseases, or they may increase the risk of being affected by certain 
disease conditions - such as celiac disease. Using molecular genetics tools, such as genetic 
linkage and association approaches, it is possible to locate and identify these variations.  
3.1.1. HLA genes 
The MHC region on human chromosome 6p21.3 is the most polymorphic region in the entire 
human genome. The allelic diversity of certain genes is extremely high, e.g. the HLA-B gene 
has more than 1100 known alleles and the HLA-DRB1 gene has more than 600 known alleles 
(IMGT/HLA Database: http://www.ebi.ac.uk/imgt/hla/allele.html - 12.02.2009) (Robinson et 
al. 2003). The celiac disease-associated DQB1 and DQA1 genes have 96 and 35 alleles, 
respectively. The MHC region harbours several genes that have crucial roles in controlling 
and regulating immune responses. The HLA genes can be divided into three classes according 
to their main functions (Figure 3): HLA class  I  and  II  genes  are  responsible  for  presenting  
antigens; HLA class III genes comprise a more heterogenic group of various, mostly immune-
related genes. 
  
Figure 3 The HLA region on chromosome 6 and HLA class II genes. The celiac disease-associated 
DQA1 and DQB1 genes are highlighted with black. HLA-DQB3, HLA-Z and HLA-DPA3 
are pseudogenes.  
HLA genes are associated with several autoimmune and inflammatory disorders (McDevitt 
1998, Reveille 2006) such as ankylosing spondylitis (with B27), narcolepsy (with 
DQB1*0602), type 1 diabetes (with DRB1*0301-DQB1*0201 and DRB1*04-DQB1*0302), 
rheumatoid arthritis (with DRB1*0401/0404/0405/0101), systemic lupus erythematosus (with 
DRB1*0301/*1501/*1503/*08), Sjögren’s syndrome (with DRB1*0301), systemic sclerosis 
(with DRB1*11/*0301/*1502), and autoimmune thyroid disease (Graves’ disease and 
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autoimmune thyroiditis) (with DRB1*0301-DQA1*0501-DQB1*0201 haplotype). Some of 
these associations are relatively weak, whereas for other diseases the particular HLA 
haplotype is always required for disease onset. Certain HLA haplotypes show a particularly 
strong association with celiac disease, which was demonstrated as early as 1972 by Falchuk 
and Strober, and by Stokes et al. The strongest association signal was subsequently refined to 
the HLA class II molecules DR3 and DQ2 (Keuning et al. 1976, Solheim et al. 1976, Tosi et 
al. 1983). 
Approximately 90% of European Caucasians with celiac disease carry the HLA-DQ2 
heterodimer coded by the DQA1*05 and DQB1*02 alleles (Sollid et  al. 1989, Karell et al. 
2003). A majority of the patients carry the DQ2.5 (or DR3-DQ2) haplotype, where the alpha 
and beta chains of the DQ2 heterodimer are encoded together in cis on a DRB1*03 haplotype 
(including the DRB1*03, DQA1*0501 and DQB1*0201 alleles). The DQ2 heterodimer can 
also be encoded in in trans configuration by the DQ2.2 (DR7-DQ2) and DQ7 (DR5/6-DQ7) 
haplotypes, with the DQA1*05 allele deriving from DRB1*11, *12 or *13 haplotypes 
(DRB1*11/12/13, DQA1*0505, DQB1*0301) and the DQB1*02 allele deriving from a 
DRB1*07 haplotype (DRB1*07, DQA1*02, DQB1*0202) (Mazzilli et al. 1992, Sollid and 
Thorsby 1993).  
The DQ8 heterodimer encoded by the DR4-DQ8 haplotype (DRB1*04, DQA1*03, 
DQB1*0302) is common in celiac patients who do not carry the DQ2 heterodimer (Spurkland 
et al. 1992). As explained in Chapter 2.4.1, both DQ2 and DQ8 heterodimers have a central 
role in the pathogenesis of celiac disease (Molberg et al. 1998). Only a small number of 
patients do not carry DQ2 or DQ8, and the vast majority of these patients carry one chain of 
the DQ2 heterodimer - i.e. encoded by either the DQ2.2 or DQ7 haplotype (Karell et al. 2003, 
Polvi et al. 1998). The HLA haplotypes and heterodimers conferring risk to celiac disease are 
illustrated in Figure 4. 
The HLA DQ2 and DQ8 heterodimers are necessary but not sufficient, on their own, for 
the development of celiac disease, as they are common also in the healthy population (Sollid 
et al. 1989, Polvi et al. 1996). This indicates that there are other risk genes for celiac disease 
in the human genome. Several attempts have been made to identify the non-HLA risk genes 
and genetic variants for celiac disease. Along with increasing knowledge about variation in 
the human genome, as well as innovations to genotyping methodology, our understanding of 
the genetic factors predisposing to celiac disease is growing.  
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Figure 4 A. HLA haplotypes conferring risk to celiac disease. The DQ2 heterodimer (coded by 
DQA1*05 and DQB1*02) can derive either in cis or in trans configuration. The 
frequencies shown are taken from Karell et al. (2003). B. The DQ heterodimer consists of 
an alpha chain and a beta chain encoded by the DQA1 and DQB1 genes, respectively.  
3.1.2. Genome-wide linkage studies and positional candidate genes 
The genome-wide linkage study approach is a method to locate disease susceptibility loci, and 
this method has been highly successful in identifying risk loci for monogenic, Mendelian, 
diseases. The method employs families with at least two affected individuals, genetic markers 
(e.g. microsatellites or single-nucleotide polymorphisms [SNP]), and recombination fractions 
or shared chromosomal segments between the affected siblings or other family members. This 
method works best for rare disease alleles with relatively high penetrance, and it is robust 
against allelic heterogeneity. No prior hypothesis or knowledge is needed in relation to which 
chromosome the risk-conferring genes may be located because the whole genome is under 
inspection. Encouraged by findings for Mendelian disorders, the linkage method has been 
widely used in attempts to locate risk genes for diseases with complex aetiology. 
The first genome-wide linkage scan in celiac disease was published in 1996 (Zhong et al. 
1996). Since then, 12 other whole-genome linkage scans have been performed (Greco et al. 
1998, King et al. 2000, Naluai et al. 2001, Liu et al. 2002, Woolley et al. 2002, Popat et al. 
2002a, Neuhausen et al. 2002, Van Belzen et al. 2003, van Belzen et al. 2004, Rioux et al. 
2004, Garner et al. 2007, Ding et al. 2008). With the exception of the MHC locus, the results 
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of the linkage scans have been somewhat contradictory. However, a number of chromosomal 
regions have been repeatedly highlighted, e.g. 5q31-33 (CELIAC2) (Greco et al. 1998, Naluai 
et al. 2001, Liu et al. 2002), 2q32 (CELIAC3) (King et al. 2000, Naluai et al. 2001, Rioux et 
al. 2004) and 19p13 (CELIAC4) (Popat et al. 2002a, Van Belzen et al. 2003, van Belzen et al. 
2004) (Table 1).  
 
CELIAC2 locus on chromosome 5q31-q33 
The CELIAC2 locus has been linked with celiac disease in genome-wide linkage scans in the 
Italian, Swedish-Norwegian and Finnish populations (Greco et  al. 1998, Naluai et al. 2001, 
Liu et  al. 2002). This region also showed linkage in a Finnish candidate locus study 
(Holopainen et al. 2001). A meta- and pooled-analysis performed in Italian, Finnish, Swedish, 
Norwegian, French and UK populations revealed strong linkage of this region with celiac 
disease, suggesting that the region is the strongest non-HLA susceptibility locus for celiac 
disease (Babron et al. 2003). The locus harbours several genes related to immune responses, 
such as the Th2 cytokine cluster and interleukin genes, making it highly interesting for celiac 
disease and other inflammatory diseases. Chromosome 5q31-q33 has also been associated 
with several other autoimmune and inflammatory disorders, such as Crohn’s disease, type 1 
diabetes, asthma, psoriasis and rheumatoid arthritis, further emphasising its role in 
inflammatory conditions (Rioux et al. 2001, Morahan et al. 2001, Cookson and Moffatt 2000, 
Samuelsson et al. 1999, Tokuhiro et al. 2003). Nevertheless, no consistent gene associations 
have been found in the region to date. 
Two systematic fine-mapping studies of the CELIAC2 locus have been published recently 
(Amundsen et al. 2007, Adamovic et al. 2008b). The aim of these studies was to identify 
genetic variants responsible for the previously identified linkage signal in the Scandinavian 
population (Naluai et al. 2001). Adamovic et al. (2008b) reported strong evidence for linkage 
of the locus with celiac disease, and modest association was also demonstrated. Amundsen et 
al. (2007) found several single- and multi-point associations albeit at modest significance 
levels. However, no risk variants were confirmed in these two partly overlapping studies, 
implying an incomplete coverage of the 5q31-q33 region and highlighting the need for studies 
with greater statistical power. 
 
CELIAC3 locus on chromosome 2q32 
The CELIAC3 locus on chromosome 2q32 has shown linkage with celiac disease and several 
other autoimmune diseases (Gough et al. 2005). This region harbours the CTLA4, ICOS and 
CD28 genes, all of which belong to the CD28 family of T cell co-stimulatory receptors 
expressed on T cells following activation. CD28 is required for the activation of T cells 
(Yamada et al. 2002). In contrast, CTLA4 is a negative regulator of T cell responses and may 
be required for the induction of tolerance (Yamada et al. 2002). It mediates the effects of 
regulatory T cells known to be important in suppressing immune responses (Rudd 2009). 
ICOS is necessary for the maintenance of humoral immunity, as it is involved in antibody 
isotype-switching and also induces the secretion of Th2 cytokines (Shilling et al. 2006). 
A number of studies have suggested that CTLA4 and ICOS are the strongest candidate 
genes in the region. Despite several fine-mapping attempts, the risk-conferring genetic factor 
still remains unknown. Association of the CTLA4 region and celiac disease has been reported 
in several populations (Popat et al. 2002c, Hunt et al. 2005, Brophy et al. 2006). However, 
ICOS appears to give the strongest linkage and association signals in the Finnish population 
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(Holopainen et al. 2004, Haimila et al. 2004, Haimila et al. 2009). The linkage disequilibrium 
(LD) pattern in the region is complex, consisting of two main haplotype blocks: one covering 
CTLA4 and the first exon of ICOS, and the other spanning the rest of ICOS. This makes it 
challenging to pinpoint the risk gene using genetic approaches. Population heterogeneity in 
the region may also explain the inconsistent results.  
 
CELIAC4 locus on chromosome 19p13 
The chromosomal region 19p13 (CELIAC4) has shown evidence for genetic linkage with 
celiac disease, with the strongest reported linkage signal coming from the Dutch population 
(Van Belzen et al. 2003, van Belzen et al. 2004). A subsequent fine-mapping study comprised 
of 463 cases and 686 controls from the Dutch population revealed association of five SNPs in 
the 3’ end of the myosin IXB gene (MYO9B) with celiac disease (Monsuur et al. 2005). The 
function of MYO9B, also known as unconventional myosin, is relatively poorly understood. It 
is a single-headed processive motor that contains a Rho-GTPase-activating protein domain 
(O'Connell and Mooseker 2003) similar to genes involved in tight junction functions (Matter 
and Balda 2003, Bruewer et  al. 2004). Thus, it is possible that variations in MYO9B play a 
role in the impairment of epithelial permeability of the small intestine (Matter and Balda 
2003), leading to increasing amounts of gluten entering the lamina propria. The MYO9B 
association with celiac disease has also been replicated in the Spanish population (Sanchez et 
al. 2007), as well as in other pathologies, such as inflammatory bowel disease (van 
Bodegraven et al. 2006, Nunez et al. 2007a, Cooney et al. 2009), schizophrenia (Jungerius et 
al. 2008), refractory celiac disease (Wolters et al. 2007), systemic lupus erythematosus 
(Sanchez et al. 2007), rheumatoid arthritis (Sanchez et al. 2007) and type 1 diabetes (Santiago 
et al. 2008). Despite these numerous associations, MYO9B still remains a controversial 
candidate gene for celiac disease and inflammatory bowel disease because several replication 
studies in different populations have not found association (Hunt et al. 2006, Amundsen et al. 
2006a, Amundsen et al. 2006b, Giordano et al. 2006, Nunez et al. 2006, Latiano et al. 2007, 
Cirillo et al. 2007). Such variable results could be explained by differences in allele 
frequencies in different populations, lower risk effect than estimated in the original 
association study, or differences in LD patterns within the gene region. In addition, the 
possibility of other risk gene(s) in the region cannot be excluded because MYO9B is  in  LD  
with genes located both upstream and downstream.  
 
CELIAC5 locus on chromosome 15q11-q13 
Given that the results of the genome-wide linkage scans had been somewhat contradictory, 
perhaps due to genetic heterogeneity between different populations, Woolley et al. (2002) 
performed a genome-wide linkage scan in a relatively homogenous subpopulation to decrease 
the effects of underlying allelic and locus heterogeneity. The subpopulation originated from 
North-Eastern Finland, from the Koilliskaira region. Genealogic studies had confirmed that 
the families selected for this study shared a common ancestor in the 16th century, in a region 
which belongs to the so-called late settlement region in the Finnish population history. Due to 
a small founder population settling in these regions, leading to genetic drift and bottlenecks in 
Eastern and Northern Finland, several rare disease genes have become enriched in the region. 
Likewise, many diseases that are common in other parts of Europe are absent there. The 
population structure in these regions, representing a relatively homogenous genetic 
background, has been ideal in identifying genes causing monogenic diseases. The genetic 
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background of homogenous regional isolates with long blocks of LD is also thought to be 
useful in dissecting diseases with a more complex genetic background (Peltonen et al. 1995). 
Indeed, there are some examples where this approach has been successful (Laitinen et al. 
2004).  
Woolley et al. (2002) identified a region on chromosome 15q11-q13 (CELIAC5) as a 
potential genetic susceptibility locus for celiac disease. This region still requires confirmation 
as a true susceptibility locus for celiac disease in larger populations. 
In general, the findings of genome-wide linkage scans in celiac disease mirror the results 
from genome-wide linkage scans performed for other complex diseases. The linkage scans 
have  highlighted  several  chromosomal  regions  of  the  human genome,  but  replication  of  the  
original results has often proved to be challenging and further fine-mapping studies have 
frequently not revealed genetic associations that completely explain the original observed 
linkage signals. (Risch 2000). 
3.1.3. Functional candidate genes 
Studies on functional candidate genes attempt to test whether a particular gene with a known 
function is genetically linked or associated with the disease of interest. The candidate gene 
can be selected based on existing knowledge of its possible role in disease pathogenesis. A 
gene can also be selected as a candidate gene based on known associations with similar or co-
occurring diseases, which imply shared genetic risk factors. In addition, genes showing 
interesting expression patterns, e.g. in studies with whole-genome expression arrays, are often 
tested for genetic association. 
Several candidate gene studies have been performed in celiac disease, with particular 
interest in genes having a known immunological function (Lopez-Vazquez et al. 2002, Rueda 
et al. 2004, Curley et al. 2006, Abel et  al. 2006, Santin et al. 2007, Wapenaar et al. 2007, 
Nunez et  al. 2007b, Castellanos-Rubio et al. 2008, Chernavsky et al. 2008). These studies 
include genes that are related to both innate and adaptive immunity. Combined positional and 
functional candidate gene studies have also been used in celiac disease, applying both 
knowledge relating to the function of the gene and its location within candidate susceptibility 
loci for the disease. Epithelial barrier integrity is impaired in the small intestine of patients 
with celiac disease, so genes known to relate to tight junction assemblies have also been 
tested as susceptibility candidates (Wapenaar et al. 2008). Similarly, genes that have shown 
association with other autoimmune or inflammatory disorders have been tested for association 
with celiac disease (Alizadeh et  al. 2007, Santin et al. 2008, Nunez et  al. 2008). Recent 
findings of celiac disease candidate gene studies are summarised in Table 2.  
Many of the candidate gene studies do not confirm associations to the tested variants, or 
only weak evidence for association is found. The lack of confirmed association through this 
experimental approach may reflect the insufficient knowledge we have about gene functions 
and/or biochemical pathways involved in the pathogenesis of celiac disease. The inability to 
replicate findings may also be caused by overestimations of possible effect sizes, especially in 
studies conducted using relatively small samplesets. Replication of reported associations in 
different samplesets and populations are essential for validating novel findings. 
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3.1.4. Genome-wide association studies 
The sequencing of the entire human genome, completed at the beginning of the millennium, 
has opened up new possibilities for understanding the structure and variations of the human 
genetic material (Lander et  al. 2001, Venter et  al. 2001). This information can be used for 
studying susceptibility variants for human diseases and for asking more targeted questions in 
gene mapping. Another important approach for understanding the architecture of the human 
genome is the International HapMap Project, which aims to unravel the LD patterns and 
common variation of the human genome in different populations (International HapMap 
Consortium 2003, International HapMap Consortium et  al. 2007). Information about 
conserved haplotype blocks in the genome can be used in capturing most of the common 
patterns of variation within the genome, providing an essential tool for the study of genetic 
susceptibility factors for diseases. 
Together with increasing amounts of information on genomic variation, new genotyping 
methods have been developed that enable simultaneous and fast genotyping of hundreds of 
thousands of SNPs in a large number of samples. These innovations have given rise to 
genome-wide association studies, where up to one million genetic markers can be genotyped. 
Such  an  approach  allows  the  whole  human  genome  to  be  simultaneously  tested  as  disease  
susceptibility candidates. Genome-wide association studies have opened up a new era in the 
genetic research of complex diseases, with novel findings that were not detected using the 
genome-wide linkage approach.  
Genome-wide association studies are an ideal way to study common risk variants for 
common diseases. Given that the effect size of identified risk variants has been relatively low 
in many of diseases, large sample materials are required to obtain sufficiently high statistical 
power for analysis. Typically, at least several hundred cases and controls are used in these 
studies. By the end of February 2009, 261 genome-wide association studies had been 
published, reporting associations to 1183 SNPs in 178 diseases and traits (Hindorff et  al. 
2009) (http://www.genome.gov/26525384). In most of the common diseases, genome-wide 
association studies have revealed several independent loci with low effect sizes, suggesting 
that genetic susceptibility for common diseases is a result of joint effects of various risk-
conferring variants.  
The first genome-wide association study in celiac disease was published in 2007. It was 
performed to identify novel risk factors in the British population and examined 778 unrelated 
cases and 1422 population controls (van Heel et al. 2007). The strongest findings detected in 
the scan at the non-HLA regions were replicated in the Dutch (508 cases, 929 controls) and 
Irish (486 cases, 560 controls) populations. This study identified and confirmed the 
KIAA1109-TENR-IL2-IL21 gene cluster on chromosome 4q27 (CELIAC6) as a risk locus for 
celiac disease (van Heel et al. 2007). This association with celiac disease has recently been 
replicated in the Swedish-Norwegian (Adamovic et al. 2008a) and Italian populations 
(Romanos et al. 2009); the association has also been demonstrated in other autoimmune and 
inflammatory diseases, such as type 1 diabetes, rheumatoid arthritis and ulcerative colitis 
(Todd et  al. 2007, Zhernakova et al. 2007, Albers et al. 2009, Festen et al. 2009). 
Interestingly, a previous meta-analysis combining genome-wide linkage studies from the 
Italian, British, Swedish-Norwegian and Finnish populations also showed evidence for 
linkage to this locus (Babron et al. 2003).  
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Due to the extensive LD in the 4q region, the risk-causing variant associated with celiac 
disease still remains to be determined. This LD block contains three known protein-coding 
genes: TENR, IL2, IL21, and a predicted gene KIAA1109 with an unknown function. The 
TENR gene is expressed mainly in the testis (Schumacher et al. 1995), making it an unlikely 
risk gene for intestinal inflammatory diseases. In contrast, KIAA1109 is expressed in multiple 
tissues (NCBI UniGene EST Profile Viewer: http://www.ncbi.nlm.nih.gov/sites/entrez) and 
cannot be excluded as a candidate for celiac disease. IL2, formerly known as T cell growth 
factor,  is  secreted by antigen stimulated T cells and plays an important role in T cell  and B 
cell activation and proliferation (Lowenthal et al. 1985, Smith 1988). IL21 has a role in 
enhancing  the  proliferation  and  IFN  production  of  T  cells,  B  cells  and  natural  killer  cells  
(Kasaian et al. 2002, Brandt et al. 2007, Ettinger et al. 2005), and it has also been implicated 
in the Th17 pathway (Korn et al. 2007). These important immunological functions make IL2 
and IL21 highly interesting candidate genes for celiac disease, as well as other immunological 
disorders. However, further investigations are required to determine the functional risk 
variants within this LD block.  
Intriguingly, the two strongest non-HLA susceptibility loci for celiac disease identified in 
linkage studies (CELIAC2 and CELIAC3)  showed only weak evidence for association in the 
2007 genome-wide association study. The MYO9B region on chromosome 19p13 (CELIAC4) 
showed no association signal at all. 
The genome-wide association study by van Heel et al. (2007) was followed-up by a study 
of >1000 of the most strongly associated non-HLA SNPs and was performed in the UK (719 
cases, 1561 controls), Irish (416 cases, 957 controls) and Dutch (508 cases, 888 controls) 
populations. This study revealed several loci that are likely to be important for celiac disease 
susceptibility (Hunt et  al. 2008). Seven previously unknown risk regions were identified 
(Table 3); six of them harbouring genes controlling immune responses (Hunt et al. 2008). 
The most significantly associated region outside the HLA region and the previously 
identified KIAA1109-TENR-IL2-IL21 region was located within an LD block containing the 
regulator of G-protein signalling 1 (RGS1) gene on chromosome 1q31 (CELIAC7) (Hunt et 
al. 2008). The RGS1 association has recently been replicated in Italian patients with celiac 
disease (Romanos et al. 2009), and in British patients with type 1 diabetes (Smyth et  al. 
2008). Genes belonging to the RGS family are involved in attenuating the signalling activity 
of G proteins by acting as GTPase-activating proteins. RGS1 is known to regulate chemokine 
receptor signalling and it is involved in B cell activation and proliferation (Kehrl 1998). Hunt 
et al. (2008) detected RGS1 expression in small intestinal biopsies, providing further evidence 
for the involvement of RGS1 in celiac disease. Interestingly, RGS1 is expressed at higher 
levels in intestinal intraepithelial lymphocytes than in systemic T cells (Shires et  al. 2001). 
Intestinal epithelial lymphocytes appear to have a key role in epithelial cell death and the 
development of villous atrophy in celiac disease (Hue et al. 2004). 
Another region showing strong association with celiac disease in the Hunt et al. study 
(2008) is located on chromosome 2q11-q12 (CELIAC8), harbouring four genes (IL1RL1, 
IL18R1 IL18RAP, SLC9A4) in strong LD with each other. Two intergenic SNPs, located 
within the same 400 kilobase (kb) LD block, showed strong evidence for association with 
celiac disease (Hunt et al. 2008). It is not yet clear how the risk variants at this locus 
contribute to celiac disease susceptibility. IL1RL1 and SLC9A4 are not expressed in small 
intestinal tissue; thus, they are unlikely to contribute to the aetiology of celiac disease but 
cannot be completely excluded (Hunt et al. 2008). IL18R1 and IL18RAP form the receptor for 
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IL18, making both genes very good candidates for celiac disease susceptibility because Th1 
inflammatory responses characterised by the expression of IFN  and active IL18 cytokine are 
found in mucosal samples of untreated celiac patients (Salvati et al. 2002). Hunt et al. (2008) 
found that genotypes that increased disease risk correlated with different (lower) mRNA 
expression of IL18RAP, but not of IL18R1, pointing to a primary role for IL18RAP. 
Association to this locus was not replicated in Italian (Romanos et  al. 2009) or in Spanish 
(Dema et al. 2009) patients with celiac disease, suggesting that this locus is not associated 
with celiac disease in the Southern European populations. Alternatively, the region may 
confer a weaker risk effect than estimated in the previous studies. Association of this locus 
with type 1 diabetes has been reported in British patients (Smyth et al. 2008) and also with 
inflammatory bowel disease in Dutch patients (Zhernakova et al. 2008). 
Hunt et al. (2008) also identified a genetic variant within a large cluster of chemokine 
receptor genes on chromosome 3p21 (CELIAC9). The SNP providing the strongest 
association signal in this locus was located between the CCR3 and CCR2 genes,  both  of  
which encode receptors for chemokines. This locus is also associated with celiac disease in 
the Spanish population (Dema et al. 2009), but not in the Italian population (Romanos et al. 
2009). The inability to replicate the finding may reflect population heterogeneity or a weaker 
effect size in the Italian population than previously estimated. This locus does not appear to 
be associated with type 1 diabetes, as was previously reported in the British population 
(Smyth et al. 2008). 
A 70 kb LD block on chromosome 3q25-q26 (CELIAC10) showed strong association with 
celiac disease in the Hunt et al. study (2008), and subsequently also in the Italian population 
too (Romanos et al. 2009). This region is located immediately upstream of the IL12A gene. 
Together with IL12B, IL12A forms the heterodimeric IL12 molecule which has a broad range 
of biological activities on T cells and natural killer cells. Interestingly, IL12 is required for 
Th1 lineage differentiation and induces IFN  secretion by T cells, which are both shown to be 
important in celiac disease. 
Several  SNPs  within  a  70  kb  LD  block  on  chromosome  3q28  (CELIAC11) showed 
association with celiac disease in the study by Hunt et al. (2008). The SNP showing strongest 
association in this region is located in an intron of the LIM domain containing preferred 
translocation partner in lipoma (LPP) gene. Not much is known about the LPP gene, but it is 
highly expressed in the small intestine (Hunt et al. 2008) and is also known to have an 
important role in cell adhesion (Petit et al. 2003). However, it is not known how LPP would 
contribute to the pathogenesis of celiac disease. The LPP region also showed modest 
association with celiac disease ain the Italian population (Romanos et al. 2009). 
Another susceptibility locus for celiac disease is located on chromosome 6q24.1 
(CELIAC12), harbouring the T cell activation RhoGTPase activating protein (TAGAP) gene 
(Hunt et al. 2008): modest association with celiac disease was also found in the Italian 
population (Romanos et al. 2009). TAGAP is  associated  with  type  1  diabetes  in  the  UK  
population (Smyth et al. 2008) and this locus has also shown evidence for linkage in a large 
Dutch pedigree (van Belzen et al. 2004). TAGAP is expressed during T cell activation (Mao et 
al. 2004) and presents with three different isoforms (NCBI Entrez Gene: 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene), but little is known about its functions.  
The seventh newly identified risk locus by Hunt et al. (2008) is located on chromosome 
12q24 (CELIAC13).  Genetic  variants  situated  close  to  the  SH2B adaptor  protein  3  (SH2B3) 
gene, also known as lymphocyte adaptor protein (LNK),  were  found  to  increase  the  risk  of  
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celiac disease. The association results have been replicated in the Italian population (Romanos 
et al. 2009) and strong association with type 1 diabetes has also been reported in this region 
(Todd et al. 2007). SH2B3 is involved in mediating interactions between extracellular 
receptors and intracellular signalling pathways in T cell activation (Li et al. 2000, Takaki et 
al. 2000, Buza-Vidas et al. 2006). Hunt et al. (2008) demonstrated expression of SH2B3 in 
the small intestine, with increased expression levels in untreated celiac biopsies that possibly 
reflects the leukocyte recruitment and activation observed in celiac disease (Hunt et al. 2008).  
As the strongest association signals yielded in the genome-wide association study by van 
Heel et al. (2007) had been investigated further by Hunt et al. (2008), Trynka et al. (2009) 
examined the variants that showed modest association with celiac disease in the 2007 
genome-wide association study. 458 SNPs were selected for genotyping in 1682 cases and 
3258 controls from three populations (UK, Irish and Dutch). The results were combined with 
the initial UK data from the 2007 genome-wide association study, and showed association to 
eight SNPs. These SNPs were also genotyped in an independent cohort from Italy (538 cases 
and 593 controls). The combined analysis revealed the strongest association signals within the 
OLIG3-TNFAIP3 locus on chromosome 6p23.3 and the REL locus on chromosome 2p16.1. 
The OLIG3-TNFAIP3 locus is associated with rheumatoid arthritis (Plenge et al. 2007, 
Thomson et al. 2007), systemic lupus erythematosus (Musone et al. 2008, Graham et al. 
2008), type 1 diabetes (Fung et  al. 2009) and psoriasis (Nair et al. 2009). REL has 
demonstrated modest evidence for association with ulcerative colitis (Zhernakova et al. 
2008). OLIG3 is involved in the development of neurons of the dorsal horn of the spinal cord 
(Muller et al. 2005), making it an unlikely susceptibility gene for autoimmunity. Both 
TNFAIP3 and REL are involved in the NF-kappa-B signalling pathway, which has a role in 
innate immunity (Belguise and Sonenshein 2007, Lee et al. 2000, Boone et al. 2004, Turer et 
al. 2008). However, no difference was observed in TNFAIP3 or REL mRNA expression levels 
between untreated celiac patients and controls. Small intestinal biopsy samples and whole 
blood samples of different genotypes demonstrated no difference in mRNA expression 
(Trynka et al. 2009), highlighting the need for further investigation of these genes in relation 
to the pathogenesis of celiac disease. 
The findings of the 2007 genome-wide association study, its follow up studies and 
replication efforts are summarised in Table 3. 
As  seen  in  other  common  complex  diseases,  the  genome-wide  association  approach  has  
been highly successful in finding new susceptibility genes in celiac disease as well. More 
novel risk loci have been found and confirmed in this single scan and its follow-up studies 
than with any other experimental approach used previously. Most importantly, these results 
appear to be replicable in other populations and similar diseases, further validating the initial 
findings. Nevertheless, further studies are required to pinpoint the risk genes within the LD 
blocks and identify the risk-causing variants, as well as to characterise the function of the 
variants in the pathogenesis of celiac disease. 
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Aims of the study 
The broad aim of this study was to investigate genetic susceptibility loci for celiac disease in 
the Finnish, Hungarian and Italian populations. The specific aims were to: 
 
1. Screen for previously reported genetic susceptibility loci for celiac disease in the 
Hungarian population (I).  
 
2. Fine-map and use candidate gene analysis at the 5q31-q33 (CELIAC2) locus, with the 
ultimate goal of identifying risk genes and variants for celiac disease (I) 
 
3. Evaluate the role of the 19p13 (CELIAC4) locus and the MYO9B gene in celiac 
disease in the Finnish and Hungarian populations (II). 
 
4. Evaluate the role of the IL18RAP locus in celiac disease in the Finnish, Hungarian and 
Italian populations (III). 
 
5. Validate a novel genotyping method for HLA risk haplotypes in celiac disease (IV). 
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Materials and methods 
1. Study subjects 
Study subjects were drawn from Finland, Hungary and Italy. The number of families and 
independent cases and controls from each population used in each project are presented in 
Table 4 and the study materials are described in detail below. 
Table 4 The number of Finnish, Hungarian and Italian samples used in each of the 
 publications. 
 Finland Hungary Italy (Trieste) 
Italy 
(Milan) 







I 277 189* / 176* 374 258 / 403   
II 158 (45 with DH)  
337 (39 
with DH) 
270 (62 with 
DH) / 270   
III 282# 844 / 698 342# 607 / 448 187 / 239  
IV 85 210 / 176  177 / 179 134 / 202 543 / 592 
*Two SLC36A2 SNPs were genotyped for additional 375 Finnish cases and 310 population controls. 
#The family materials overlapped partially with the single cases. 
1.1. Finnish population 
The Finnish sample material consisted of two different family collections, independent single 
cases with celiac disease, and population controls. 
The Finnish family and single patient cohorts were collected at the Paediatric Research 
Centre,  University  of  Tampere  Medical  School  and  Tampere  University  Hospital.  The  first  
collection of Finnish celiac disease families (158 families in total) has been described earlier 
(Mustalahti et al. 2002b). The additional collection of family materials commenced in 2006 
and is still ongoing. Both collections are based on screening family members of affected 
individuals for silent celiac disease. Earlier diagnoses were re-evaluated by scrutinising 
medical records and performing antibody screenings to reveal asymptomatic cases among 
family members. Diagnosis was based on initial small bowel biopsy (or skin biopsy for DH 
patients) and/or EMA positivity. Over 90% of patients fulfilled the strict diagnostic criteria. 
The Finnish single case material consisted of patients with celiac disease or DH, and they 
were independent of the family materials. The diagnoses were made or re-evaluated using the 
same criteria as described for the families. 
The Finnish controls were selected to be representative for the Finnish population and 
were part of four larger datasets. One dataset was chosen to be representative for the Finnish 
population density excluding Lapland and Northern Karelia. These samples were used in 
publications I, III and IV. The second set of control samples was collected at the University of 
Tampere, and they have been shown by antibody testing and biopsy to be negative for celiac 
disease and were used in publications I and IV. The third control set was a population-based 
sample of Finnish monozygotic twins described previously (Aulchenko et al. 2009), and the 
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fourth set was part of a national cohort collected to provide a comprehensive picture of the 
health  state  of  the  Finnish  population.  The  details  of  this  fourth  cohort  have  also  been  
previously described (Aromaa and Koskinen 2004, Stefansson et al. 2008). The third and 
fourth control sets were used in publication III. The controls matched the geographical spread 
of the patients, which represented the general (mixed) Finnish population with a slight bias to 
Southern Finland and Tampere region.  
1.2. Hungarian population 
The Hungarian celiac disease material consisted of pedigrees where at least one offspring was 
affected with celiac disease. In addition, a set of unrelated patients with celiac disease was 
also studied. The Hungarian patient material was collected at the Coeliac Disease Center, Pal 
Heim Children’s Hospital, Budapest, and at the Department of Paediatrics, University of 
Debrecen, and new samples have been collected throughout this Ph.D. candidature. Diagnosis 
of the Hungarian patients was based on initial small bowel biopsy (or skin biopsy from DH 
patients) and/or EMA positivity. As in the Finnish patient collection, over 90% of the patients 
fulfilled the strict diagnostic criteria having both severe villous atrophy and EMA positivity; 
the remaining patients were diagnosed based on serology or histology. All DH patients were 
shown to have granular IgA deposition in their skin by direct immunofluorescence.  
The Hungarian single case material consisted of patients with celiac disease or DH, and 
was independent of the family material. The diagnoses were made or re-evaluated using the 
same criteria as described for the families.  
The Hungarian population control material consisted of samples representing the 
Hungarian population according to the population density. The details of the Hungarian 
control population have been described earlier (Central Statistical Office 2001, Széles et al. 
2005). 
1.3. Italian population 
The Italian samples were collected from two distinct regions of Italy. The first set was from 
Trieste in North-Eastern Italy, the second set was from Milan in Northern Italy. All celiac 
patients were diagnosed in accordance with the ESPGAN criteria (Working group of 
European Society of Paediatric Gastroenterology and Nutrition 1990) and the intestinal 
biopsies were analysed using Oberhuber’s classification (Oberhuber et al. 1999). In addition, 
the patients’ serum samples tested positive for both anti-TGM2 antibody and anti-EMA. 
The two sets of Italian population controls were selected to geographically match the 
Italian patient sets.  
1.4. Ethical permits 
The collection of patient and control materials was approved by the ethical committees of the 
Tampere and Helsinki University Hospitals, Finnish National Public Health Institute, Heim 
Pal Children’s Hospital, Budapest, the University of Debrecen, the Independent Local Ethical 
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Committee of the Burlo Garofolo Children's Hospital in Trieste and the hospital Fondazione 
IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy. All 
enrolled participants were informed about the study according to the study protocol and gave 
written informed consent. 
2. Methods 
2.1. DNA extraction 
Genomic DNA was extracted from whole blood samples by a standard non-enzymatic 
method, using the Flexigene DNA kit or the QIAamp DNA Blood Mini Kit (Qiagen GmbH, 
Hilden, Germany). 
2.2. Marker selection 
(I) Microsatellite markers and SNP markers were selected based on 11 previous genome-wide 
linkage scans and fine-mapping studies showing linkage with celiac disease in different 
populations (Zhong et al. 1996, Greco et al. 1998, King et al. 2000, Naluai et al. 2001, Liu et 
al. 2002, Woolley et  al. 2002, Van Belzen et al. 2003, van Belzen et  al. 2004, Rioux et al. 
2004, King et al. 2001, Greco et al. 2001). The selected markers were used for a linkage 
screen in the Hungarian sib-pair families with celiac disease. The markers and their genetic 
positions are listed in Table 5. 
The SNPs at the CELIAC2 locus on 5q31-q33 were selected to tag immunologically 
interesting candidate genes as listed in Table 6. The tag-SNP selection was performed in the 
CEU population genotype data downloaded from www.hapmap.org with the Tagger program 
using aggressive tagging, implemented in Haploview (v. 3.3) (de Bakker et al. 2005, Barrett 
et al. 2005), using a minor allele frequency of 0.10, minimum haplotype frequency of 0.05, 
and r2 of 0.80. The FGF1, YIPF5 (SMAP5), TCERG1, STK32A, JAKMIP2 and SPINK1 genes 
showed strongest association results in recent articles by Amundsen et al. (2007), and 
Adamovic et al. (2008b) and thus were also genotyped in this study. The SLC36A2 gene was 
chosen for typing because it was the only gene in the genome-wide association study (van 
Heel et al. 2007) that showed evidence for association at the CELIAC2 locus.  
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Table 5  The microsatellite markers and SNPs selected for the linkage screen in the Hungarian 
 sib-pair families. Marshfield centimorgan (cM) map was used to determine the genetic 
 positions of the markers.  
Chromosome Marker cM position Chromosome Marker cM position 
D1S243 0.00 D5S410 156.00 










rs231775 199.12 D9S925 32.00 
ICOS-693G/A / 
rs11883722 199.13 D9S1679 44.00 
ICOSivs+173T/C / 






rs10932037 199.16 D11S1760 12.00 
ICOSc2373G/C / 
rs4675379 199.17 D11S1999 17.00 
2 
D2S1271 199.20 D11S4190 27.00 
D4S412 5.00 D11S904 34.00 
D4S3009 23.00 D11S935 46.00 
D4S2960 29.00 D11S4142 111.00 
4 
D4S2639 33.00 CD3D 114.00 




CAh17a 136.30 D15S1002 15.00 














(II) The four SNP markers within the MYO9B gene  were  selected  based  on  the  previously  
reported association results by Monsuur et al. (2005) (rs2305767, rs1457092, rs2305764) and 
Van Bodegraven et al. (2006) (rs1545620) (Figure 5).  
(III) The two SNPs (rs13015714 and rs917997) located in the LD block containing the 
IL18RAP gene were selected for genotyping based in the previous association results by van 
Heel et al. (2007) and Hunt et al. (2008) (Figure 6). 
(IV) The six HLA risk haplotype tagging SNPs (rs2187668, rs2395182, rs4713586, 
rs7775228, rs4639334, rs7454108) were selected for genotyping based on the publication by 
Monsuur et al. (2008), where these SNPs were shown to correlate with haplotypes known to 
be associated with celiac disease. See Table 7 and Figure 7 for details. 
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Table 6  The genes and SNPs selected for the positional candidate gene analysis at the 
 CELIAC2 locus on chromosome (chr) 5q31-q33. Mb: megabases 
Gene Description Tagging SNPs Position on chr 5 (Mb) 





IRF1 interferon regulatory factor 1 
rs17622656 131.849 
IL5 interleukin 5 rs2069812 131.908 
rs2070874 132.038 IL13 & IL4 interleukin 13 & interleukin 4 
rs4426908 132.051 
rs2069885 135.256 IL9 interleukin 9 
rs1859430 135.258 
rs756462 135.396 
rs11738979 135.402 TGFBI transforming growth factor, beta-induced 
rs4141306 135.403 
rs4914 139.992 CD14 CD14 antigen 
rs2569190 139.993 









FGF1 fibroblast growth factor 1 
rs10067332 142.022 
rs5020191 143.518 
rs4289587 143.518 YIPF5 (SMAP5) Yip1 domain family, member 5 
rs6864640 143.520 
rs2163770 145.810 TCERG1 transcription elongation regulator 1 
rs11743333 145.819 
rs31036 146.595 
rs31037 146.596 STK32A serine/threonine kinase 32A 
rs1424293 146.683 
rs17107298 147.183 SPINK1 serine peptidase inhibitor, Kazal type 1 
rs3777125 147.184 
rs372402 148.732 IL17B interleukin 17B 
rs353268 148.737 
rs17111145 149.762 
rs2288817 149.767 CD74 CD74 antigen 
rs7724855 149.772 
rs13357969 150.732 SLC36A2 solute carrier family 36 (proton/amino acid symporter), member 2 rs7708940 150.769 
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Figure 5 The LD pattern in the MYO9B region on chromosome 19p13 in the CEU HapMap 
population (International HapMap Project: http://www.hapmap.org). The locations of 
the four genotyped SNPs (rs2305767, rs1545620, rs1457092, rs2305764) are marked 
with *. 
 
Figure 6 The LD pattern in the IL18RAP region on chromosome 2q12 in the CEU HapMap 
population (International HapMap project: http://www.hapmap.org). The locations of the 
two genotyped SNPs (rs13015714 and rs917997) are marked with *. 
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 VIC FAM       
rs2395182 G T C__11409965_10 32521295 DQ2.2 T  
rs4639334 A G C__42975350_10 32710192 DQ7 A  
rs2187668 C T C__58662585_10 32713862 DQ2.5 T  
rs7775228 C T C__29315313_10 32766057 DQ2.2 C  
rs4713586 A G C__27950246_10 32767560 DQ2.2  G  




Figure 7 The LD pattern in the HLA region on chromosome 6p21.3 in the CEU HapMap 
population. (International HapMap project: http://www.hapmap.org). The locations of 
the six HLA tag SNPs are marked with *. 
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2.3. Power analysis (I, II, III) 
Power analyses to detect associations to the Dutch MYO9B risk variants in the Monsuur et al. 
study (2005), the IL18RAP risk variants in the Hunt et al. study (2008) and the SLC36A2 risk 
variants in the van Heel et al. study (2007) were performed assuming a disease prevalence of 
1% and using risk parameters reported in the original studies, and significance level 0.05 was 
used. For the case-control datasets we used the Power for Association With Error program 
(http://linkage.rockefeller.edu/pawe/pawe.cgi) (Gordon et al. 2002, Gordon et al. 2003) or the 
Genetic Power Calculator program (http://pngu.mgh.harvard.edu/~purcell/gpc/) using the 
Case-control for discrete traits option. For the families, we used the Genetic Power Calculator 
program (http://pngu.mgh.harvard.edu/~purcell/gpc/) using the TDT for discrete traits option 
(Purcell et al. 2003).  
The power analysis for the MYO9B variants showed 92% power for the Hungarian case-
control set and 89% power for a TDT of Finnish and Hungarian trios. The power analysis for 
85 trios with DH showed 47% power, and 56% power for 100 Hungarian DH cases and 270 
controls. 
Our power to detect association of IL18RAP to celiac disease was 66% in the Hungarian 
case-control dataset, 74% in the Finnish case-control dataset and 27% in the Italian case-
control dataset. 
The power to detect association to the SNPs in SLC36A2 was analysed in the Finnish case-
control materials. The power of an allelic test to detect association in the 189 Finnish cases 
and 176 controls was as low as 39%. Therefore, the number of cases and controls was 
increased (564 and 486, respectively) to yield power of >80%.  
2.4. Genotyping 
2.4.1. Microsatellite markers (I) 
114 Hungarian affected sib-pair and multiplex families were genotyped for the microsatellite 
markers listed in Table 5 (I). The microsatellites were assayed using fluorescent-labelled 
primers and the ABI PRISM 3730 DNA analyser and analysed with ABI PRISM Genemapper 
(v.3)  software  (Applied  Biosystems,  CA,  Foster  City,  USA)  at  the  Department  of  Medical  
Genetics, University of Helsinki, Helsinki, Finland. 
2.4.2. SNPs (I-IV) 
Both the Sequenom (Sequenom Inc. San Diego, CA, USA) and TaqMan (Applied 
Biosystems, Foster City, CA, USA) genotyping platforms have been used for SNP genotyping 
in these doctorate studies. The Sequenom methodology is based on matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry (Sequenom Inc. San 
Diego, CA, USA) and up to 40 SNPs were multiplexed in one PCR reaction. Sequenom 
genotyping was performed either at the Finnish Genome Center, University of Helsinki, 
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Helsinki, Finland (I), or at the Mutation Analysis Facility, Karolinska Institute, Huddinge, 
Sweden (II).  
The TaqMan chemistry is based on commercially available on-demand SNP genotyping 
assays with fluorescent-labelled allele-specific probes provided by Applied Biosystems 
(Applied Biosystems, Foster City, CA, USA). The PCR reactions and allelic discriminations 
were performed using ABI PRISM 7900 Sequence Detection System instrument (Applied 
Biosystems, Foster City, CA, USA). The TaqMan genotyping was performed in our 
laboratory at the Department of Medical Genetics, University of Helsinki, Helsinki, Finland 
(I, II, III, IV). Using TaqMan methodology it is only possible to genotype one SNP at a time: 
in contrast, several SNPs can be typed simultaneously using the Sequenom platform. 
Nevertheless, TaqMan is optimal for small projects involving genotyping of only a few SNPs, 
and the methodology is relatively fast and easy to perform.  
In  publication  III,  the  SNP genotypes  of  a  subset  of  Finnish  controls  were  derived  from 
two larger studies (Stefansson et al. 2008, Aulchenko et al. 2009). The genotyping was 
performed using the HumanHap300-Duo Genotyping BeadChips (Illumina Inc., CA, USA). 
2.4.3. HLA typing (IV) 
From the Finnish family cohort selected for publication IV, 212 individuals had previously 
been genotyped for the DQB1 and DRB1 genes at the Finnish Red Cross Blood Service. The 
genotyping of the DQB1 polymorphisms was performed using the Olerup SSP DQB1 low 
resolution kit (Olerup SSP AB, Saltsjöbaden, Sweden). DRB1 genotypes were determined 
using HLA-linked microsatellite markers. This method has been described earlier by Karell et 
al. (2000). For 136 unrelated Finnish patients and 52 controls without celiac disease, the 
HLA-typing was performed using the DELFIA® Celiac Disease Hybridization Assay Kit 
(PerkinElmer Life and Analytical Sciences, Wallac Oy, Turku, Finland). This method detects 
the presence of the DQA1*05, DQB1*02 and DQB1*0302 alleles.  
From the Hungarian population, 78 patients had previously been genotyped for the DQB1 
and DRB1 polymorphisms using the Olerup SSP DQ low resolution and Olerup SSP DR low 
resolution kits (Olerup SSP AB, Saltsjöbaden, Sweden). 
Among the Italian sets, 97 of the celiac cases from the Trieste region had been previously 
genotyped for the DQB1 and DQA1 genes using the  low and  high  resolution  Dynal  Classic  
SSP DQ Kits (Dynal A.S., Oslo, Norway) based on PCR with allele-specific primers.  
2.5. Data analysis 
2.5.1. Data storage and management 
The genotype data, pedigree structures and affection status information were imported into a 
BC|GENE LIMS database (Biocomputing Platforms, Espoo, Finland). 
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2.5.2. Quality control 
In the family materials, genotyping results were tested for Mendelian errors using the 
PedCheck program (v. 1.1) (O'Connell and Weeks 1998). Mendelian inconsistency was 
solved by removing all genotypes for that marker in that family. Unlikely double or multiple 
recombinations were checked using the --best option of the Merlin program (v. 2 beta) 
(Abecasis et  al. 2002).  If  recombinations  occurred  close  to  each  other  in  an  individual,  the  
subject was omitted from the analysis. Furthermore, individual markers showing several 
recombinations were omitted from further analyses. 
In unrelated case-control samplesets, possible deviations from Hardy-Weinberg 
Equilibrium were analysed separately in the cases and controls for each population using a p-
value of 0.05 as cut-off. Hardy-Weinberg Equilibrium and genotyping call rates in each 
dataset were calculated using Haploview (de Bakker et al. 2005, Barrett et al. 2005). 
2.5.3. Linkage analysis (I-III) 
Multipoint non-parametric linkage (NPL) was tested in the Finnish and Hungarian families, 
both separately and in the combined material, using the Merlin program (v. 2 beta) (Abecasis 
et al. 2002). NPL analysis was chosen because the mode of inheritance of celiac disease is not 
known and unlikely to follow Mendelian patterns. Linkage scores (Zmean, non-parametric 
logarithm of odds [LOD]) were calculated using the NPLall statistics. The genetic positions of 
the SNP markers were interpolated using the CARTOGR program (Knuuttila et al. 2007).  
2.5.4. Transmission-disequilibrium test (TDT) (I-III) 
TDT was performed using the Genehunter program (v.2) (II, III) for single SNPs and using a 
sliding window for haplotypes comprising of up to four markers (Kruglyak et al. 1996, 
Kruglyak and Lander 1998). If there was more than one affected offspring in a pedigree, only 
the index patient or the first diagnosed sibling was selected to the analysis. In publication I, 
TDT was performed using Unphased v. 3.0.13, assuming linkage (Dudbridge 2008) because 
all affected children in the pedigrees were included in the analysis. The TDT was analysed in 
both single SNPs and haplotypes in LD blocks. LD blocks were estimated using Haploview v. 
4.1 (de Bakker et al. 2005, Barrett et al. 2005), and D’  0.8 was considered as high LD and 
used when estimating haplotypes. 
2.5.5. Association analysis in case-control materials (I-III) 
(I) Allelic, haplotypic and genotypic associations of the markers at the CELIAC2 locus were 
analysed. For the allelic and haplotypic analysis, Unphased v. 3.0.13 (Dudbridge 2008) was 
used and the haplotypes were estimated as in the family materials. The genotypic association 
was calculated using the 2 test in the R package v. 2.6.0 found at http://www.r-project.org/.  
(II) The MYO9B allele and haplotype frequency calculations were performed using the 
Haploview program (v. 3.3) (Barrett et al. 2005) in the Hungarian case-control sampleset. The 
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association was calculated separately for patients with DH and patients with only the 
intestinal form of celiac disease. A combined association analysis was also performed. The 
index patients from each family with DH were added to the case-control comparison to 
increase the statistical power of the analysis. The haplotypes of the unrelated individuals were 
constructed with the SNPHAP program (v. 1.3) (Clayton 2002). Odds ratios (OR) were 
calculated using Fisher’s exact test, and one-sided p-values were reported. 
(III) Allele and haplotype frequency calculations, as well as association analyses, were 
performed using Haploview (v. 4.0) (Barrett et al. 2005). Two sided p-values are reported and 
OR were calculated. A haplotype cut-off of > 1% was used in the controls. Combined ORs 
from different populations were calculated using the Mantel-Haenszel meta-analysis 
approach. Forest plots were constructed using rmeta v2.14 on the R platform available from 
http://cran.r-project.org/web/packages/rmeta/index.html. The Breslow-Day test for rs917997 
was significant (p-value 0.03) in a meta-analysis of our Finnish, Hungarian and Italian 
datasets combined with the previously published UK, Dutch, Irish (van Heel et al. 2007, Hunt 
et al. 2008) and Italian (Romanos et al. 2009) datasets, indicating heterogeneity of odds 
ratios. However, Cochran's Q statistic revealed no evidence of allelic heterogeneity in this 
data (p-value 0.5). 
2.5.6. Validation of the HLA tag SNP genotyping assays (IV) 
The results from the tag SNP genotypes were compared to previously established HLA 
genotypes by commercial HLA typing kits and HLA-linked microsatellite markers. The DQ-
types were determined from the tag SNP results as described by Monsuur et al. (2008). If a 
mismatch between the two typing methods was found, the DQ type was verified in our 
laboratory using the Olerup SSP DQB1 and DRB1 low  resolution  kits  (Olerup  SSP  AB,  
Saltsjöbaden, Sweden). DQ-typing results obtained by traditional typing methods and the tag 
SNP approach were compared to evaluate the sensitivity, specificity, positive predictive value 
and correlation (r2)  of  the  test  using  GraphPad  Prism  4  (GraphPad  Software,  La  Jolla,  CA,  
USA). From family materials, all available family members with sufficient DR-DQ data were 
counted, but only one patient per family was selected for the haplotype frequency estimations. 
2.6. Electrophoretic mobility shift assay (II) 
The sequence spanning the SNP rs2305764 in the MYO9B gene was analysed with the 
Consite program (http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite), and a putative 
transcription factor binding site was observed. Double-stranded 41 base pair (bp) probes 
(CTGATGCCGAGGCATATACG[A/G]CCCCCTTTTTGTGTGAGTGT) spanning the 
rs2305764 SNP were thus designed for an electrophoretic mobility shift assay (EMSA). The 
probes were 32P radio-labelled and incubated with nuclear extracts of HeLa cells according to 
Murumägi et al. (2003). As a negative control, probes were incubated with nuclear extraction 
buffer alone. After 30 min incubation, the samples were separated using non-denaturing gel 
electrophoresis and visualised by autoradiography (Murumägi et al. 2003). To test the 
specificity of the bound nuclear protein(s) to the rs2305764 SNP sequence, EMSA was 
competed with the addition of excess unlabelled probes. 
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2.7. Western blot (II, III) 
(II)  Two  commercial  antibodies  against  MYO9B  were  tested  for  Western  blotting  using  
peripheral blood mononuclear cells (PBMC) and small intestinal biopsy samples. We were 
not  able  to  produce  reliable  staining  results,  due  to  either  non-specific  or  complete  lack  of  
staining. 
(III) PBMCs were purified from buffy coats of anonymous blood donors by density 
gradient centrifugation and cultured for 72 hours in complete RPMI-1640 media. Western 
blot was performed on the samples according to standard protocols with reducing (SDS) 
conditions. Cell lysates of the collected samples (40µg) were treated with Complete Protease 
Inhibitor Cocktail (Roche Diagnostics GmbH, Germany) according to the manufacturer’s 
instructions. Membranes were stained with 1 µg/ml mouse anti-human IL18RAP (clone 4G4, 
Abnova, Taiwan), and with anti-beta-actin antibody for loading control (clone 8226, Abcam, 
UK) after stripping. HRP-conjugated goat anti-mouse IgG (Abcam, UK) was used as 
secondary antibody for detection with Western Lightning Chemiluminescence Reagent Plus 
(PerkinElmer LAS, Inc., Boston, USA). Statistical comparison between carriers and non 
carriers of rs917997 allele A was performed using GraphPad Prism 4. Only one sample had 
the genotype AA, so it was grouped with the heterozygotes in the analysis. 
2.8. Peripheral blood mononuclear cell cultures and enzyme-linked 
immunosorbent assay (III) 
Cryopreserved PBMCs from 38 healthy donors were cultured for 22 h in X-VIVO15 media 
(Lonza, USA) with anti-CD3-anti-CD28 beads (Invitrogen, UK) at a ratio of 1:5 beads:cell 
with/without IL18 (R&D systems, UK) at doses 0 ng/ml, 1 ng/ml, 10 ng/ml and 100 ng/ml. 
All  donor samples were cultured in triplicate in 96-well  plates on the same day to eliminate 
experiment and batch variation. IFN  was measured in the supernatants by enzyme-linked 
immunosorbent  assay  (ELISA)  (E-Bioscience,  CA,  USA),  and  the  mean  of  triplicate  wells  
was analysed. Statistical comparison between the three stratified rs917997 genotype groups 
was performed using curve-fit regression analysis accounting for dose-response (GraphPad 
Prism 4). 
2.9. Immunohistochemical analysis (II, III) 
(II) Two commercial antibodies against MYO9B were tested for immunohistochemical 
staining of frozen and paraffin-embedded intestinal biopsies. Ten intestinal samples were 
analysed from the following subjects: 3 adults with untreated celiac disease who were positive 
for serum IgA class EMA, 4 adults with treated celiac disease (on a strict gluten-free diet for 
at least one year) who were EMA-negative, and 3 healthy control subjects who were EMA-
negative and had normal villous structure. One of the treated celiac disease patients was 
known  to  be  negative  for  the  putative  risk-conferring  genotypes;  one  was  known  to  be  
positive for the risk-increasing genotype. Unfortunately, reliable staining results were not 
produced (data not shown). 
Materials and methods 
50 
(III) IL18RAP protein expression was analysed by staining formalin-fixed, paraffin-
embedded biopsy samples from 5 untreated (1 homozygous for the risk haplotype, 4 
homozygous for the protective haplotype) and 9 treated (5 homozygous for the risk haplotype, 
4 homozygous for the protective haplotype) patients with celiac disease, as well as 5 controls 
(2 homozygous for the risk haplotype, 3 homozygous for the protective haplotype), with 5 
µg/µl mouse anti-human IL18RAP (clone 4G4, Abnova, Taiwan). Mouse IgG2a kappa (5 
µg/µl;  clone  MG2a-52,  Abcam,  UK)  was  used  as  an  isotype  control  on  each  slide.  Epitope  
unmasking was performed by boiling at 95°C in 10 mmol/l citrate buffer, pH 6.0, for 1 min + 
1 min, and immunohistochemistry was performed using Vectastain Elite ABC kit (Vector 





1. Linkage screen of 11 candidate loci in Hungarian families (I) 
The 114 Hungarian affected sib-pair and multiplex families were analysed for genetic linkage 
using 40 microsatellite markers and 10 SNPs in 11 previously reported candidate loci for 
celiac disease. The results of the analysis are shown in Table 8. Markers on chromosomal 
regions 5q31-q33 and 19p showed the strongest evidence for genetic linkage, although none 
of the results reached statistical significance.  
2. Fine-mapping of the CELIAC2 locus on chromosome 5q31-q33 (I) 
2.1. Linkage in Finnish and Hungarian pedigrees 
The CELIAC2 locus on chromosome 5q31-33 showed evidence for linkage in the Hungarian 
pedigrees, and it has previously been shown to be linked with celiac disease in Finland and 
multiple other populations (Zhong et al. 1996, Greco et al. 1998, Naluai et al. 2001, Liu et al. 
2002, Woolley et  al. 2002, Greco et al. 2001). Thus, we fine-mapped this locus in large 
Finnish and Hungarian family materials, including both multiplex and trio families, partially 
overlapping with the families that were studied in the previous linkage scans in the Hungarian 
population (within this study) and also from the Finnish population (Holopainen et al. 2001, 
Liu et al. 2002).  
On chromosome 5q31-q33, 48 SNPs tagging 17 genes were successfully genotyped in a 
total of 651 Finnish and Hungarian families. The 138 Finnish families that were informative 
for linkage analysis demonstrated some linkage to the whole region (maximum Zmean 2.66, 
p=0.004 at 140.02 – 140.04 cM) (Figure 8). The 134 Hungarian families informative for 
analysis showed a weaker linkage signal to the region (maximum Zmean 2.10, p=0.02 at 
148.07 – 148.08 cM) (Figure 8). The combined Finnish and Hungarian family material gave a 
maximum Zmean of 3.22, (p=0.0006 at 149.51 cM) (Figure 8).  
2.2. Association analysis in Finnish and Hungarian pedigrees and case-control 
materials 
TDT was analysed in the Finnish and Hungarian families. The analysis revealed association 
of different genes with celiac disease in the two populations. The alleles and haplotypes 
demonstrating nominal association are shown in Tables 9 and 10, respectively. 
Allelic, genotypic and haplotypic association in the cases and controls was also analysed. 
None of the associations demonstrated in the Finnish and Hungarian families were replicated 




Table 8  Results of the linkage screen of candidate loci for celiac disease in 114 Hungarian 











p-value Linkage previously shown by: 
1p 2.1-17.7 3 -0.57 0.70 King et al. 2000,  Liu et al. 2002 
2q33 (CELIAC3) 201.4-204.7 9 0.44 0.30 
Naluai et al. 2001,  
Rioux et al. 2004, 
Holopainen et al. 2004, 
Naluai et al. 2000 
4p 3.4-18.5 4 0.76 0.20 Liu et al. 2002,  Woolley et al. 2002 
5q31-q33 
(CELIAC2) 132-168.2 12 1.51 0.06 
Holopainen et al. 2001, 
Greco et al. 1998,  
Naluai et al. 2001,  
Liu et al. 2002,  
Greco et al. 2001 
7q 95.9-104.0 2 0.05 0.50 Zhong et al. 1996,  Liu et al. 2002 
9p 18.3-33.9 4 0.90 0.20 
Naluai et al. 2001,  
Liu et al. 2002,  
van Belzen et al. 2004 
11p-q 5.3-125.6 9 0.07 0.50 
Zhong et al. 1996,  
Greco et al. 1998,  
King et al. 2000,  
Woolley et al. 2002,  
van Belzen et al. 2004, 
King et al. 2001 
15q (CELIAC3) 25.5-32.8 3 0.36 0.40 Woolley et al. 2002 
16q 71.8-81.5 2 0.91 0.20 
King et al. 2000,  
Liu et al. 2002,  
van Belzen et al. 2004 
19p (CELIAC4) 16.1-19.9 2 1.38 0.08 Van Belzen et al. 2003  and 2004 
 
Figure 8  Linkage results for a 20 centimorgan (cM) region on chromosome 5q31-q33 in the 





Table 10 Haplotype TDT in Finnish and Hungarian families and in Finnish cases and controls. 
 In the TDT, case frequencies refer to the allele frequencies in the affected offspring and 
 the control frequencies refer to the number of non-transmissions of the alleles, and also 
 transmissions to unaffected offspring. P-values  0.05 were considered significant; only 
 significant results are shown. 
Finnish families    
SLC36A2 (2 SNPs) p-value = 0.002    
Haplotype Freq. cases, controls OR 95% C.I. 
A-A 0.47, 0.55 reference  
G-A 0.04, 0.07 0.67  0.24 - 1.85 
G-G 0.49, 0.35 1.59 1.06 – 2.39 
    
Hungarian families    
IL3 (2 SNPs) p-value = 0.002    
Haplotype  Freq. cases, controls OR 95% C.I. 
C-C 0.79, 0.73 reference  
C-T 0.15, 0.14 0.96 0.67 - 1.38 
T-T 0.06, 0.13 0.43 0.26 - 0.72 
OR: odds ratio, C.I.: confidence interval 
3. Linkage and association study of MYO9B, a positional candidate 
gene at the CELIAC4 locus (II) 
Given that MYO9B demonstrated  strong  association  with  celiac  disease  in  the  Dutch  
population (Monsuur et  al. 2005), and our evidence for linkage in this region with the 
Hungarian population (I), we examined MYO9B genetic variants in our sample collections. In 
total, 1265 Finnish and Hungarian patients with gluten intolerance were included in the study, 
of which 161 (13%) suffered from DH. The putative risk haplotype identified in the study by 
Monsuur et al. (2005) is referred to as A-G-A-A.  
3.1 Linkage in Finnish and Hungarian pedigrees 
All four markers showed significant linkage to celiac disease in the combined Finnish and 
Hungarian material of 240 multiplex families, with the maximum NPL LOD score of 3.76 
(p=0.00002); Table 11.  
The gut and skin manifestations of gluten intolerance were also analysed separately. That 
is, the families were divided in two groups according to presence (or absence) of any DH in 
the families. Linkage and association of the four MYO9B SNPs were studied in a total of 85 
DH families. The MYO9B region showed linkage to DH in the combined material of 47 
multiplex families (non-parametric LOD score of 1.13, p=0.01; Table 11). In the Finnish 
families, the region showed stronger linkage in DH families than in non-DH families; the 11 
Hungarian affected sib-pair families did not have enough power to show linkage to DH. 
Although there were only 47 pedigrees with DH in this study (i.e. one-fifth of the pedigrees), 
their contribution to the linkage score was considerable (contributing to approximately one-
third of the total LOD score). 
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Table 11  Results of the NPL test in the Finnish and Hungarian pedigrees. LOD: non-
 parametric LOD score, N: number of informative families. The LOD scores with a p-
 value <0.05 are shown in bold. DH: families with dermatitis herpetiformis, NON-DH: 
 families without any DH. 
 Hungarian and Finnish families Hungarian families Finnish families 
Diagnosis group LOD p-value N LOD p-value N LOD p-value N 
All (DH+NON-DH) 3.76 0.00002 240 3.09 0.00008 131 0.83 0.03  109 
NON-DH 2.57 0.0003 193 2.60 0.0003 120 0.22 0.2  73 
DH 1.13 0.01 47 0.35 0.10 11 0.68 0.04 36 
3.2. No association in the large Finnish and Hungarian family cohorts 
No association of the MYO9B marker alleles or haplotypes with celiac disease was found in 
the large Hungarian and Finnish family materials (Table 12).  
Table 12 Results of the allele and haplotype TDT in the Hungarian and Finnish pedigrees with 
 only one affected child per family included in the analysis. The number of 
 transmissions/non-transmissions (T/NT) is shown. Families with and without DH are 
 included.  
 Hungarian and Finnish families Hungarian families Finnish families 
Marker*allele T/NT  2 p-value T/NT  2 p-value T/NT  2 p-value 
rs2305767*A 140 / 129 0.45 0.50 101 / 92 0.42 0.52 39 / 37 0.05 0.82 
rs1545620*G 124 / 138 0.75  0.387 86 / 98 0.78 0.38 38 / 40 0.05 0.82 
rs1457092*A 124 / 137 0.65 0.42 88 / 99 0.65 0.42 36 / 38 0.05 0.82 
rs2305764*A 134 / 140 0.13  0.72 98 / 102 0.08 0.78 36 / 38 0.05 0.82 
AGAA 
haplotype 78 / 88 0.60  0.44 51 / 63 1.26 0.26 27 / 25 0.08 0.78 
GTCG 
haplotype 87 / 88 0.01  0.94 58 / 58 0.00 1.00 29 / 30 0.02 0.90 
3.3. Putative association in the Hungarian patients with dermatitis 
herpetiformis 
The TDT of the combined Hungarian and Finnish DH family material revealed that none of 
the SNPs are significantly associated with DH (Table 13). However, an independent TDT 
analysis  of  the  Hungarian  DH families  showed that  three  of  the  SNPs  were  associated  with  
DH, the most significant being rs2305764 (p=0.003) (Table 13). The Dutch risk haplotype A-
G-A-A  was  over-transmitted  to  the  offspring  in  the  Hungarian  families  with  DH  (12  
transmitted vs. 1 non-transmitted, p=0.002). Moreover, the opposite haplotype G-T-C-G was 




Table 13  TDT results of the Finnish and Hungarian pedigrees with patients presenting DH, the 
 skin manifestation of gluten intolerance. The number of transmissions/non-
 transmissions (T/NT) is shown. P-values  0.05 were considered significant and are 
 shown in bold. 
 Hungarian and Finnish families Hungarian families Finnish families 
Marker*allele T/NT 2 p-value T/NT 2 p-value T/NT 2 p-value 
rs2305767*A 22 / 13 2.31  0.13 16 / 4 7.20 0.007 6 / 9 0.60 0.44 
rs1545620*G 18 / 11 1.69 0.19 10 / 3  3.77 0.05 8 / 8 0.00 1.0  
rs1457092*A 19 / 11 2.13 0.14 13 / 3  6.25 0.01 6 / 8 0.29 0.59 
rs2305764*A 24 / 13 3.27 0.07 18 / 4 8.91 0.003 6 / 9 0.60 0.44 
AGAA 
haplotype 15 / 7 2.91 0.09 12 / 1 9.31 0.002 3 / 6 1.00 0.32 
GTCG 
haplotype 7 / 15 2.91 0.09 1 / 12 9.31 0.002 6 / 3 1.00 0.32 
 
Hungarian gluten-sensitive patients without DH showed the reverse trend in the TDT 
analysis: the A-G-A-A haplotype was under-transmitted to patients (p=0.02; Table 14). In 
Finnish families, gluten intolerance both with and without DH was not found to be associated 
with any marker or haplotype using TDT analysis (Tables 13 and 14). 
Table 14 TDT results of the Finnish and Hungarian pedigrees with only the intestinal form of 
 gluten intolerance. The number of transmissions/non-transmissions (T/NT) is shown. 
 P-values  0.05 were considered significant and are shown in bold. 
 Hungarian and Finnish families Hungarian families Finnish families 
Marker*allele T/NT 2 p-value T/NT 2 p-value T/NT 2 p-value 
rs2305767*A 116 / 116 0.00 1.00 85 / 88 0.05 0.82 33 / 28 0.41 0.52 
rs1545620*G 100 / 125 2.78 0.10 76 / 95 2.11 0.15 30 / 32 0.06 0.80 
rs1457092*A 103 / 126 2.31 0.13 75 / 96 2.58 0.11 30 / 30 0.00 1.00 
rs2305764*A 108 / 127 1.54 0.22 80 / 98 1.82 0.18 30 / 29 0.02 0.90 
AGAA 
haplotype 61 / 81 2.82 0.09 39 / 62 5.24 0.02 24 / 19 0.58 0.45 
GTCG 
haplotype 80 / 71 0.54 0.46 57 / 46 1.17 0.28 23 / 27 0.32 0.57 
 
Association was examined further in the Hungarian population using an independent case-
control sampleset (270 cases, 270 controls), which included 62 additional DH patients. Allele, 
genotype and haplotype frequencies of the Hungarian singleton patients were compared to 
respective frequencies in the Hungarian control population; 38 index patients from the 
Hungarian families with DH were also added to the comparison. Differences in frequencies 
were not statistically significance, but suggested that individuals homozygous for the Dutch 
risk-haplotype alleles to have a higher risk of DH than the heterozygotes or individuals 
homozygous for the alternative haplotype alleles. The A-G-A-A haplotype frequency for the 
DH cases was 41.5%, compared to 35.4% for the controls (OR 1.30, p=0.07, 95% CI 0.93 - 
1.82). Conversely, the G-T-C-G haplotype frequency for the DH cases was 31.2% compared 
to 37.9% for controls (OR 0.74, p=0.05, 95% CI 0.52 - 1.05). Individuals homozygous for the 
A-G-A-A haplotype had an increased risk of DH (OR 1.74, p=0.06, 95% CI 0.92 - 3.29), 




3.4. Electrophoretic mobility shift assay results 
The function of the highest risk-conferring SNP rs2305764 found in the Dutch population 
(Monsuur et  al. 2005) was examined further using EMSA to determine its effect on gene 
regulation. The SNP is located in intron 28 (at 141 bp from exon 28 and 123 bp from exon 29) 
of the MYO9B gene, and is at a possible binding site for transcription factors. No difference in 
the binding of nuclear proteins was detected between the two alleles (Figure 9). 
 
Figure 9 A. Schematic view of the location of the SNP rs2305764 in the intronic region between 
exons 28 and 29 in the MYO9B gene. 41 base pair (bp) probes spanning the SNP 
rs2305764 were designed for electrophoretic mobility shift assay (EMSA).B. EMSA 
results show that the sequence around the rs2305764 SNP binds nuclear protein(s) from 
HeLa nuclear extract. Identical electrophoretic mobility shift patterns marked by arrows 
were produced with both A (risk) and G alleles. C. The specificity of the binding of 
nuclear protein(s) in the rs2305764 SNP sequence. Binding of factors can be competed 
out with excess addition of unlabelled (‘cold’) probes. In addition, EMSA can also be 
competed out with the reciprocal addition of cold oligos, suggesting that the same 
protein(s) are binding to the oligos bearing the rs2305764 SNP alleles G and A shown by 
arrow. Free labelled probes are marked by arrowheads.  
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4. Association study of the IL18RAP locus in celiac disease (III) 
The IL18RAP region was first implicated in celiac disease in a genome-wide association study 
by van Heel and colleagues in 2007, and subsequently confirmed as a novel risk locus by 
Hunt et al. in 2008. Since novel gene associations should be validated in multiple populations, 
we studied the risk-conferring variants within the IL18RAP region in our celiac disease 
materials.  
4.1. No evidence for linkage or association in the Finnish or Hungarian families 
Finnish and Hungarian family materials did not show genetic linkage or association with the 
two markers at the IL18RAP locus. Linkage analysis was conducted in 109 Finnish families, 
yielding a LOD score of 0.16 (p=0.2), and 107 Hungarian families (LOD 0.09, p=0.3). TDT 
analysis found no evidence for transmission disequilibrium in either population (Finnish: 
45/49 p=0.7, Hungarian: 97/78, p=0.2). These results may be (partially) explained by the low 
information content from analysis of only two bi-allelic markers that are in strong LD.  
4.2. Association in the case-control materials 
Table  15  shows the  association  analysis  results  of  the  two SNPs  at  the  IL18RAP locus and 
their haplotypes in Finnish, Hungarian and Italian case-control materials. Carriage of 
rs13015714*G and rs917997*A was significantly associated with increased risk for celiac 
disease in the Hungarian case-control material (p=0.001, OR 1.38, 95% CI 1.14-1.68 and 
p=0.001, OR 1.39, 95% CI 1.14-1.70, respectively). The corresponding GA haplotype 
demonstrated association (p=0.0001, OR 1.48, 95% CI 1.21-1.80) with disease-risk in 
Hungarian cases, whilst the TG-haplotype showed protection (p=0.0040, OR 0.75, 95% CI 
0.62-0.91). Significant association to celiac disease was not found in the Finnish or Italian 
populations, although frequency differences between cases and controls showed the same 
tendency as in the Hungarian samples, as well as the previous UK and Dutch studies.  
Meta-analysis of our Finnish, Hungarian and Italian datasets combined with previously 
published UK (van Heel et al. 2007, Hunt et al. 2008), Dutch (Hunt et al. 2008), Irish (Hunt 
et al. 2008) and Italian (Romanos et al. 2009) datasets demonstrated strong association of the 
IL18RAP locus SNPs with celiac disease (Figure 10). The OR for carriage of rs917997 was 
1.25 (p=1.89x10-11, 95% CI 1.17-1.33). Meta analysis of our Finnish, Hungarian and Italian 




Table 15 IL18RAP allele and haplotype association results in Finnish, Hungarian and Italian 










cases, controls p-value OR 95% CI 
Finnish 844 698 rs13015714 G 0.21, 0.19 0.07 1.18 0.98-1.41 
   rs917997 A 0.21, 0.19 0.09 1.17 0.98-1.40 
    TG 0.78, 0.81 0.05 0.84 0.70-1.00 
    GA 0.21, 0.19 0.14 1.14 0.96-1.37 
Hungarian 607 448 rs13015714 G 0.31, 0.24 0.001 1.38 1.14-1.68 
   rs917997 A 0.30, 0.24 0.001 1.39 1.14-1.70 
    TG 0.68, 0.74 0.004 0.75 0.62-0.91 
    GA 0.30, 0.22 0.0001 1.48 1.21-1.80 
    GG 0.01, 0.02 0.04 0.46 0.21-0.97 
    TA 0.01, 0.02 0.12 0.58 0.26-1.28 
Italian 187 239 rs13015714 G 0.28, 0.26 0.47 1.14 0.80-1.61 
   rs917997 A 0.28, 0.24 0.23 1.24 0.87-1.76 
    TG 0.71, 0.74 0.35 0.85 0.60-1.20 
    GA 0.28, 0.24 0.27 1.22 0.86-1.74 
    GG 0.01, 0.02 0.27 0.41 0.08-1.97 
n: number of analysed samples, OR: odds ratio, C.I.: confidence interval 
 
Figure 10  Meta-analysis of our populations combined with those of van Heel et al. (2007), Hunt et 
al. (2008) and Romanos et al. (2009) for the IL18RAP SNPs rs917997. The number of the 
subjects in each population, association p-values and odds ratios (carriage of risk allele) 
are shown. Box sizes correspond to sample sizes of each population. 
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4.3. IL18RAP expression and function in blood leucocytes 
Expression levels of IL18RAP were studied in PBMCs from anonymous blood donors by 
Western blot. Figure 11A shows IL18RAP protein in PBMCs from 16 blood donors 
genotyped for rs917997. Two bands of differing size both appeared to be specific for 
IL18RAP. A 70-kilodalton (kDa) protein, which corresponds to the estimated full-length 
IL18RAP, was visible in 15 out of 16 donors. One sample demonstrated two proteins of 
approximately 70-kDa in size (lane 1). A protein of 37-kDa was also present in 14/16 PBMC 
samples. Carriers of the risk allele rs917997*A (AA and AG genotypes) demonstrated higher 
expression levels of the 37-kDa protein than non-carriers, but lower expression of the 70-kDa 
protein; however, these differences were not statistically significant (Figure 11B).  
 
Figure 11  A. IL18RAP expression in unstimulated peripheral blood mononuclear cells (PBMCs). 
The rs917997 genotypes for the PBMC samples are as follows: AA, lane 5; AG, lanes 1-4 
and 13-16; GG, lanes 6-12. The lowest band at ~25 kDa is not specific for IL18RAP 
because it was also present upon staining with secondary antibody only. B. Densitometric 
analysis of the 37-kDa and 70-kDa bands standardised over beta-actin levels and 
grouped by rs917997 genotype.  
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IL18 induced IFN  secretion in a dose–dependent manner in polyclonally-stimulated (anti-
CD3/CD28) PBMCs (Figure 12), but not in resting cells. However, the rs917997 IL18RAP 
genotypes showed no difference in PBMC responsiveness among 38 healthy donors. 
 
Figure 12 IFN  secretion peripheral blood mononuclear cells (PBMCs) stimulated with anti-CD3-
anti-CD28 in the presence of increasing concentration of IL18. IL18 induces IFN  
secretion in a dose-dependent manner, but the rs917997 genotypes demonstrated no 
difference in IFN  secretion. 
4.4. IL18RAP expression in small intestinal tissue 
To examine the expression of IL18RAP in celiac disease, immunohistochemical analysis of 
small  intestinal  biopsy  samples  from  untreated  and  treated  celiac  patients  and  controls  was  
performed. Mononuclear cells in the lamina propria of two samples demonstrated staining 
with a monoclonal antibody specific for IL18RAP. This staining was also observed in entero-
endocrine cells in the crypts of two samples, as well as in Paneth cells of one sample (Figure 
13A, B, and C, respectively). No differences were observed between untreated and treated 
celiac patients, between patients and controls, or individuals with different rs917997 




Figure 13 IL18RAP expression in the small intestinal tissue of treated patients with celiac disease, 
homozygous for the risk haplotype. Staining with monoclonal antibody specific for 
IL18RAP (A-C) or isotype control (D-F). 
5. Validation of HLA tag SNPs in Finnish, Hungarian and Italian 
populations (IV) 
5.1. Correlation of HLA results using old and new methodology 
To predict the DQ2.2, DQ2.5, DQ7 and DQ8 risk haplotypes for celiac disease, six tagging 
SNPs were genotyped in 400 Finnish individuals (212 from a family cohort, 136 unrelated 
patients and 52 controls), 79 Hungarian patients and 97 Trieste-Italian cases from whom 
traditional HLA genotypes were available.  
In the Finnish samples, validation of DQ2.5, DQ2.2, and DQ7 haplotypes was only 
performed for the family cohort because the presence of these haplotypes cannot always be 
determined using the DELFIA assay when the parental haplotypes are unknown. The 
validation study results are presented in Table 16, showing sensitivities and specificities 
ranging from 0.95 to 1. HLA testing using the DELFIA kit found 7 individuals to be 
DQA1*05 positive and DQB1*02 negative, implying a serotype of DQ7. Five individuals 
were DQB1*02 positive and DQA1*05 negative, and are possibly DQ2.2. Tagging SNP 
analysis to determine presence of DQ7 and DQ2.2 matched these results. 108 individuals 
were positive for both DQA1*05 and DQB1*02, and the DELFIA assay could not distinguish 
whether these subjects carried DQ2.5 or both DQ2.2 and DQ7.  However,  the  tagging  SNP  
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approach predicted 105 of these to carry the DQ2.5 haplotype, and 3 subjects had the 
DQ2.2/DQ7 genotype. 
In the Hungarian and Trieste-Italian populations, the sensitivities and specificities ranged 
from 0.99 to 1 (Table 16). 
The Finnish, Hungarian and Trieste-Italian materials were also analysed together for the 
correlation. The overall correlation was high, the sensitivities for DQ2.2, DQ2.5, DQ7 and 
DQ8 ranging from 0.97 to 1, and the specificities ranging from 0.996 to 1 (Table 16). 
Table 16  Validation of HLA tag SNPs in Finnish, Hungarian and Italian (Trieste) samples. 
 All: Finland, Hungary and Italy combined, PPV: positive predictive value, r2: 
 correlation 
DQ2.2 Finland Hungary Italy (Trieste) All 
Number of chromosomes 
tested 354 152 166 672 
Sensitivity 1 1 1 1 
Specificity 1 1 1 1 
PPV 1 1 1 1 
r2 1 1 1 1 
conflicting results 0 0 0 0 
 
DQ2.5 Finland Hungary Italy (Trieste) All 
Number of chromosomes 
tested 388 158 186 732 
Sensitivity 0.98 1 1 0.99 
Specificity 0.99 1 1 0.99 
PPV 0.99 1 1 0.99 
r2 0.94 1 1 0.97 
conflicting results 0.015 0 0 0.008 
 
DQ7 Finland Hungary Italy (Trieste) All 
Number of chromosomes 
tested 422 158 186 766 
Sensitivity 1 1 1 1 
Specificity 1 0.99 0.99 0.997 
PPV 1 0.95 0.97 0.97 
r2 1 0.94 0.96 0.97 
conflicting results 0 0.006 0.0005 0.0026 
 
DQ8 Finland Hungary Italy (Trieste) All 
Number of chromosomes 
tested 736 158 192 1086 
Sensitivity 0.95 1 1 0.97 
Specificity 0.999 0.99 0.99 0.996 
PPV 0.98 0.88 0.83 0.93 
r2 0.93 0.87 0.82 0.81 
conflicting results 0.0041 0.006 0.01 0.0055 
 
Out of all the 576 tested individuals, 12 (2.1%) showed different results in the tagging SNP 
assay when compared to the traditional HLA typing results. Nine of them were celiac disease 
affected individuals from the Finnish family cohort, one was a Hungarian celiac patient and 
two were  Italian  (Trieste)  celiac  patients.  In  addition,  four  patients  from the  Italian  (Milan)  
sampleset were predicted to have three HLA alleles by the tag-SNP method but when 
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genotyped for the DQB1 and DRB1 genes using the Olerup SSP low-resolution kits, two of 
the samples showed a rare DR11-DQ2 haplotype. 
5.2. HLA haplotype frequencies in the population materials 
The six HLA risk haplotype tagging SNPs were also genotyped in an extended set of Finnish, 
Hungarian and Italian (Milan and Trieste) cases and controls. The HLA haplotype and 
genotype frequencies determined from the SNP allele frequencies are presented in Table 17. 
Excess of DQ2.5 among patients was seen both in haplotype (Table 17A) and carrier (Table 
17B) frequencies in all 3 populations. According to the SNP genotype results, 90.2% of the 
Finnish patients with celiac disease carried the DQ2 heterodimer (88.3% DQ2.5 and 1.9% 
DQ2.2/DQ7), and 6.4% carried the DQ8 haplotype without DQ2. Respectively, these 
frequencies among Hungarian patients were DQ2 97.2% (DQ2.5 87.5% and DQ2.2/DQ7 
9.7%) and DQ8 2.3%, and among the Italian (Trieste) patients DQ2 89.6% (DQ2.5 74.7% 
and, DQ2.2/DQ7 14.9%), and DQ8 7.5%, and among Italian (Milan) patients DQ2 88.4% 
(DQ2.5 64.1% and DQ2.2/DQ7 24.3%) and DQ8 6.2%. 
A dose effect of DQ2.5 homozygosity on celiac disease risk was observed in all three 
populations when comparing the genotypes of cases and population controls (Table 17B). 
Higher DQ2.2 haplotype and DQ2.5/DQ2.2 genotype frequencies were seen among the 
patients in Hungary and Italy, but to a lesser extent in Finland (Tables 17A and B). In 
addition, we studied the risk effect of the second haplotype in the presence of one DQ2.5 
haplotype in all 4 population groups (Table 17C). The Italian-Milan population was the only 
dataset with a large enough sample size for such an analysis, thus it provides the most reliable 
results. The results show that homozygosity for DQ2.5 increases the risk of celiac disease 5.5- 
fold when compared to individuals with DQ2.5/DQX (where DQX implies haplotypes other 
than DQ2.5, DQ2.2, DQ7 or DQ8), while DQ2.2 increased the risk of celiac disease 3.1-fold. 
DQ7 or DQ8 in the presence of DQ2.5 did not confer additional risk to the disease. 
Table 17  A. HLA-haplotype frequencies (%) in Finnish, Hungarian and Italian controls and 
 cases with celiac disease determined by tagging SNP analysis. The total number of 
 chromosomes is shown in brackets. B. HLA-genotype frequencies (%) in Finnish, 
 Hungarian and Italian controls and cases with celiac disease, determined by tagging 
 SNP analysis. The total number of individuals is shown in brackets. C. DQ2.5 
 stratified analysis using logistic regression and DQ2.5/DQX as the reference group. 



















DQ2.2 6.0 5.8 8.9 20.1 11.9 17.2 10.8 27.1 13.3 (DQA1*0201) 
DQ2.5 8.8 50.9 10.1 49.6 15.8 44.8 8.4 37.1 15.6 (DQB1*0201) 
DQ7 6.8 4.0 21.5 13.0 29.5 16.0 27.8 17.9 16.7 (DQB1*0301) 
DQ8 11.1 6.2 9.8 2.8 5.4 6.7 5.7 4.6 14.4 (DQB1*0302) 
DQX 67.3 33.0 49.7 14.4 37.4 15.3 47.3 13.3  
Total 100 100 100 100 100 100 100 100  
DQX: not DQ2.2, DQ2.5, DQ7, DQ8, CEU: HLA allele frequencies of the CEU population from de 






















All DQ2+ 17.6 90.2 21.8 97.2 36.1 89.6 22.5 88.4 
DQ2.5/DQX 13.6 58.5 10.1 28.4 13.4 23.1 6.9 18.3 
DQ2.5/DQ2.5 0.6 13.6 2.2 11.9 3.0 14.9 0.7 10.1 
DQ2.5/DQ2.2 0.0 6.4 1.7 29.5 3.0 15.7 2.9 23.9 
DQ2.5/DQ7 1.1 4.9 3.4 14.2 7.9 15.7 4.1 9.3 
DQ2.5/DQ8 1.7 4.9 0.6 3.4 1.5 5.2 1.5 2.4 
DQ2.2/DQ7 0.6 1.9 3.9 9.7 7.4 14.9 6.4 24.3 
 
All DQ2-, DQ8+ 19.3 6.4 17.3 2.3 8.9 7.5 9.5 6.2 
DQ8/DQX 15.9 4.2 10.1 0.0 5.0 3.7 5.0 2.6 
DQ8/DQ8 1.1 0.8 1.7 0.0 0.0 0.7 0.3 0.6 
DQ8/DQ2.2 1.7 1.1 2.2 1.1 1.0 1.5 0.7 2.1 
DQ8/DQ7 0.6 0.4 3.4 1.1 3.0 1.5 3.4 0.9 
 
All DQ2-, DQ8- 63.1 3.4 60.9 0.6 55.0 2.9 68.0 5.4 
DQ2.2/DQX 9.7 1.5 10.1 0.0 9.4 2.2 10.3 1.7 
DQ2.2/DQ2.2 0.0 0.4 0.0 0.0 1.5 0.0 0.7 1.1 
DQ7/DQX 9.1 0.8 22.3 0.6 16.8 0.0 28.4 1.3 
DQ7/DQ7 1.1 0.0 5.0 0.0 11.9 0.0 6.7 0.0 
DQX/DQX 43.2 0.8 23.5 0.0 15.3 0.7 22.0 1.3 
DQX: not DQ2.2, DQ2.5, DQ7, DQ8 
95% C.I. C. 
Population HLA genotypes p-value OR Lower Upper 
DQ2.5/DQ2.5 0.098 5.574 0.730 42.569 
DQ2.5/DQ2.2 0.998 NA NA NA 
DQ2.5/DQ7 0.994 1.006 0.214 4.740 
Finnish 
DQ2.5/DQ8 0.556 0.671 0.178 2.529 
DQ2.5/DQ2.5 0.297 1.890 0.571 6.258 
DQ2.5/DQ2.2 0.005 6.240 1.731 22.497 
DQ2.5/DQ7 0.445 1.500 0.530 4.249 
Hungarian 
DQ2.5/DQ8 0.490 2.160 0.243 19.194 
DQ2.5/DQ2.5 0.002 5.510 1.871 16.228 
DQ2.5/DQ2.2 0.000 3.073 1.644 5.744 
DQ2.5/DQ7 0.602 0.850 0.462 1.565 
Italian-Milan 
DQ2.5/DQ8 0.263 0.590 0.234 1.488 
DQ2.5/DQ2.5 0.046 2.903 1.018 8.281 
DQ2.5/DQ2.2 0.036 3.048 1.073 8.657 
DQ2.5/DQ7 0.752 1.143 0.498 2.622 
Italian-Trieste 
DQ2.5/DQ8 0.180 2.613 0.641 10.647 




The  main  focus  of  this  Ph.D.  thesis  was  the  examination  of  linkage  and  association  of  the  
5q31-q33, 19p13 and IL18RAP loci  with  genetic  susceptibility  to  celiac  disease.  The  study  
highlights the challenges of gene mapping in complex diseases. Common risk variants with 
modest risk effects and low penetrance show association when population-based strategies, 
employing large sample materials, are applied; however in the presence of allelic 
heterogeneity and perhaps rare risk variants, linkage mapping utilising family materials 
appears a more suitable approach. These issues are further discussed in the following pages. 
In addition, the novel HLA genotyping method that was developed for large-scale 
investigations is also evaluated. 
1. Strong linkage but only weak evidence for association: 
susceptibility loci on chromosomes 5q31-q33 and 19p13 
Previous genome-wide linkage scans have demonstrated that the chromosomal regions 5q31-
q33 and 19p13 constitute important susceptibility loci for celiac disease (Greco et al. 1998, 
Naluai et al. 2001, Liu et al. 2002, Popat et al. 2002a, Van Belzen et al. 2003, van Belzen et 
al. 2004, Babron et al. 2003).  Linkage  signals  in  both  these  regions  were  also  replicated  in  
this study. Linkage of the 5q31-33 locus has previously been reported in the Finnish 
population (Holopainen et al. 2001, Liu et al. 2002), but this was the first study to report 
linkage in the Hungarian population. The linkage signal from the 5q31-q33 locus appeared 
slightly stronger in the Finnish families than in the Hungarian families, while the 19p13 locus 
demonstrated a stronger signal in Hungarian families. Despite this evidence of linkage of both 
loci with celiac disease, only modest association was detected for the regions. The 5q31-q33 
region is known to harbour several genes with immunological functions, and is thus a very 
interesting candidate locus for celiac disease and other immunological-related disorders. 
However, pinpointing the associated gene(s) in this locus has been challenging. In contrast, 
chromosome 19p13 harbours a candidate gene, MYO9B, which has been shown to be 
associated with celiac disease (Monsuur et al. 2005). Our studies of the 19p13 region 
concentrated on replication of this previously reported MYO9B association. 
We selected 17 candidate genes from the 5q31-q33 locus that were located under the 
linkage peak observed in the Finnish population, and performed association analyses in both 
Finnish and Hungarian family and case-control materials. The association analyses showed 
several moderate associations, and mainly for different genes in the different datasets. These 
results are in concordance with previous fine-mapping studies (Amundsen et al. 2007, 
Adamovic et al. 2008b) in which the complexity of the CELIAC2 locus and evidence for 
multiple weak associations in the region were demonstrated. In these two previous studies, 
only moderate single- and multipoint associations were demonstrated, despite the usage of 
densely-spaced markers. Only one SNP, rs33999, located in FGF1, showed association in 
both Swedish-Norwegian families of the Adamovic et al. study (2008b) and the Finnish 
families used in our study. However, these results were not replicated in the Finnish cases and 
controls, which might also be an indication of lack of statistical power in that material. None 
of the genes and SNPs showing evidence for association in the Amundsen et al. study (2007) 
Discussion 
67 
demonstrated significant association in the Finnish or Hungarian materials. These two 
Scandinavian studies (Amundsen et al. 2007, Adamovic et  al. 2008b), which applied 
overlapping materials but different fine-mapping strategies, were unable to provide more 
conclusive association results than our study. In these two studies and ours, the association 
signals appear insufficient to account for the linkage signal observed in the study populations. 
Therefore, even a substantial increase of markers may not significantly alter our results. The 
results from all three studies still point to an insufficient sample size or strong allelic 
heterogeneity in the region.  
The CELIAC2 region only demonstrated weak evidence for association in the genome-
wide association study performed in the British population, despite being the strongest non-
HLA candidate locus for celiac disease according to genome-wide linkage studies. The 
strongest association within 5q31-q33 was observed for two SNPs in LD with the SLC36A2 
gene (van Heel et al. 2007). However, this association did not gain genome-wide significance. 
A follow-up study by Trynka et al. (2009) did not show consistent associations within this 
region either. We demonstrated some evidence for association of the two SLC36A2 SNPs with 
celiac disease in the Finnish family materials, but it was not replicated in the Finnish cases 
and controls. The Hungarian materials showed no evidence for association. The weak 
association findings and the failure to consistently replicate them may reflect genetic 
heterogeneity, differences between populations, or rare variants.  
The 19p13 region has also been implicated in susceptibility to celiac disease previously, 
most notably in Dutch linkage scans (Van Belzen et al. 2003, van Belzen et al. 2004). Fine-
mapping in the region showed association with the MYO9B gene in the Dutch population 
(Monsuur et al. 2005). MYO9B has subsequently been widely studied in European 
populations. MYO9B was associated with celiac disease, systemic lupus erythematosus, and 
rheumatoid arthritis in the Spanish population (Sanchez et al. 2007), and three studies have 
pointed to the role of this gene in inflammatory bowel disease (van Bodegraven et al. 2006, 
Nunez et al. 2007a, Cooney et al. 2009).  However,  all  other recent attempts to replicate the 
findings in celiac disease have failed in the UK, Swedish-Norwegian, Italian and Spanish 
populations (Hunt et  al. 2006, Amundsen et al. 2006a, Giordano et  al. 2006, Nunez et al. 
2006, Latiano et al. 2007, Cirillo et al. 2007). 
In our study, the Dutch risk markers of within the MYO9B region were analysed in large 
Hungarian and Finnish family sets, as well as an independent Hungarian case-control 
sampleset, and demonstrated strong linkage to celiac disease, thereby confirming the region as 
a true susceptibility locus. However, neither a single allele nor any of the haplotypes showed 
association with celiac disease when all the patient materials were combined. Instead, when 
the family material was divided into two groups according to the occurrence of DH, the Dutch 
MYO9B risk SNP alleles were found to be significantly over-transmitted to the offspring of 
families with DH. This finding was strongest in the Hungarian families with DH, but the same 
trend  was  also  seen  in  the  case-control  comparison.  No  association  was  detected  in  the  
Finnish population in any patient group, but genetic linkage was seen only in families with 
DH. Our findings suggest potential, although relatively weak, genetic differences in risk of 
the intestinal and skin manifestations of celiac disease, and emphasise the importance of more 
phenotypically detailed replication studies in larger cohorts of this small subset of patients 
with gluten intolerance.  
To date, functional evidence for a role of MYO9B in celiac disease and other diseases is 
still lacking. But, interestingly, MYO9B is more highly expressed in the skin than in the 
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intestine (NCBI UniGene EST Profile Viewer http://www.ncbi.nlm.nih.gov/UniGene/). The 
function of the non-coding highest risk SNP rs2305764 reported in the Dutch population 
(Monsuur et al. 2005) was examined further in our study. An EMSA was used to study the 
effect of this SNP on gene regulation, but no differences in the binding of nuclear proteins 
were found between the two alleles. The SNP rs2305764 may also serve as a binding site for 
splice factors, which could be tested in future studies.  
Our findings with the 19p13 region may be explained by a more heterogeneous genetic 
background amongst celiac families with only the intestinal form of the disease, compared to 
families also exhibiting DH, explaining why linkage and association were seen only in the 
latter subset. On the other hand, strong linkage was also demonstrated in the Hungarian 
families displaying only intestinal pathology. Thus, the weak DH association does not fully 
explain the linkage results. Rather, it suggests either allelic heterogeneity or completely 
different primary risk alleles or genes for gluten intolerance in the 19p13 region, or the 
presently studied haplotype block.  
Indeed, one indication of this is that the Finnish families with DH did not show 
association with MYO9B,  even  though  the  families  with  DH  showed  stronger  linkage  to  
MYO9B than the families without DH. The existence of another risk gene or haplotype may 
also explain the inability to replicate association in other reported studies. In fact, this 
haplotype block shows LD with the downstream region of MYO9B and the LD actually covers 
up to four other genes, namely MDS032, OCEL1, NR2F6 and USHBP1 (Figure 5, page 43). 
Given that this region has not been genotyped systematically in previous studies by Monsuur 
et al. (2005) or Curley et al. (2006), or in any recent replication study, more thorough analysis 
of this haplotype block is needed.  
Our results, particularly the linkage results from chromosomes 5q31-q33 and 19p13, 
strongly support the presence of genuine risk factors for celiac disease at these loci. It is 
possible that there are several variants conferring low risk or alternatively rare variants 
conferring high risk to celiac disease at these two loci, explaining the failure to find confirmed 
association in samplesets with relative small to medium sample size. In addition, the 
complexity of celiac disease; with its heterogeneous genetic background and different 
manifestations, may explain the previous failures to detect association in the 5q31-q33 locus 
or to replicate MYO9B associations in different populations. Larger samplesets and high-
throughput sequencing in these loci are likely to be required for identification of the true risk 
genes and variants. Furthermore, studies with high density SNP-coverage in multiple 
populations might help to reveal the complex genetic patterns in the regions. 
2. Association but not linkage: the IL18RAP locus on chromosome 
2q12 
The IL18RAP locus on chromosome 2q12 was shown to be associated with celiac disease in 
the genome-wide association scan by van Heel et al. (2007) and in the subsequent follow-up 
study by Hunt et al. (2008). Our study aimed to further investigate this association between 
celiac disease and polymorphisms at the IL18RAP locus. We genotyped two previously 
identified celiac disease risk SNPs at this locus in patients and controls from the Finnish, 
Hungarian and Italian populations. We replicated association of the IL18RAP locus with 
celiac disease in the Hungarian case-control dataset, but not in the Finnish or Italian datasets 
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alone. The results from the Finnish population, although not significant, suggest that variants 
at the IL18RAP locus may also be true celiac disease risk factors in the Finnish population. 
However, the risk effect is likely to be considerably smaller than in the Hungarian population. 
The frequencies of the previously reported risk alleles were higher in Italian cases than in 
controls, although the difference was not statistically significant. The low power of the Italian 
sampleset may explain our inability to replicate the association reported by Hunt et al. (2008) 
in this dataset. Alternatively, as reported by a recent study by Romanos et al. (2009), the 
IL18RAP locus may simply not be associated with celiac disease in Italian populations. 
A meta-analysis of the datasets from our study, van Heel et al. (2007), Hunt et al. (2008) 
and Romanos et al. (2009) yielded highly significant association (OR 1.25, p=1.89x10-11). 
This indicates that the IL18RAP locus is a true risk factor for celiac disease in multiple 
populations.  
The GA risk haplotype showed stronger association than any single marker in the 
Hungarian population. In contrast, the rare GG and TA haplotypes showed no risk, or perhaps 
a protective effect. Due to the strong LD between the two markers, the additional information 
gained from haplotypic analysis is limited. Therefore, genotyping of other tagging markers is 
not likely to help in further identification of risk and non-risk haplotypes. Identification of the 
primary risk-conferring variant in this haplotype is likely to require both sequencing of this 
LD block and clear functional data. 
Despite the association seen in case-control materials, Finnish and Hungarian family 
materials with celiac disease did not demonstrate linkage or association to the IL18RAP locus. 
This may be partially explained by the low information content resulting from the analysis of 
only two bi-allelic markers in nearly complete LD, and also the large number of non-
informative homozygous parents in the dataset. Additionally, the result supports the 
prevailing dogma that family studies suffer a reduction in power when detecting disease 
variants with small risk effects (OR only 1.20-1.48 in this study) and low penetrance within 
families (Risch and Merikangas 1996). Case-control settings with large sample sizes are more 
powerful to detect such minor risk factors (Risch and Merikangas 1996).  
Confirming previously reported risk factors in multiple populations increases confidence 
in novel findings, as demonstrated by the current and previous studies on the IL18RAP locus 
in celiac disease. The frequencies of the associated alleles may also vary between populations 
and affect the power of the study. The risk variants at the IL18RAP locus are relatively 
common in all currently studied populations, but do demonstrate a difference in Northern-
Southern European variation: being the least frequent in Finland and the most frequent in 
Hungary and Italy. 
It is not yet clear how IL18RAP locus risk variants would contribute to celiac disease 
susceptibility. IL18RAP is contained within a 400 kb LD block that also contains three other 
genes (IL1RL1, IL18R1, SLC9A4) (Figure 6, page 43). IL1RL1 and SLC9A4 are not expressed 
in small intestinal tissue and therefore were not considered a high priority in this study, but 
their role in pathogenesis cannot be excluded and they should be investigated further in future 
studies. IL18R1 and IL18RAP come together to form the receptor for IL18, making both of 
them very good candidate genes for celiac disease susceptibility. Further work is needed to 
confirm IL18RAP as the primary risk gene and its role in pathogenesis, and also to exclude 
IL18R1. It is also possible that these two neighbouring genes are co-regulated. However, in 
the study by Hunt et al. (2008), the disease associated genotypes correlated with lower mRNA 
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expression of IL18RAP, but no effect was observed for IL18R1: this points to a primary role 
for IL18RAP. 
The mRNA correlation shown by Hunt et al. (2008) suggests that individuals with the risk 
allele have reduced IL18RAP expression, possibly leading to lower IFN  secretion. This 
appears contradictory to the strong IFN  response seen in active celiac disease. We attempted 
to directly correlate function with genotype by measuring IFN  levels from activated PBMCs 
cultured in the presence of IL18. Although we saw a dose-dependent increase of IFN  
production in the presence of IL18, no significant differences were detected between groups 
stratified by rs917997 genotype. This experiment may have been limited by small sample 
size, the heterogenous nature of PBMCs, and the strong T cell activation induced by anti-
CD3-anti-CD28 stimulation. 
Since IL18RAP has been relatively poorly characterised to date, we studied its protein 
expression in PBMCs. In addition to the expected 70-kDa protein corresponding to the 
estimated full-length IL18RAP, we saw expression of an approximately 37-kDa protein, 
suggesting that an alternative isoform of IL18RAP exists. Although not statistically 
significant, these results suggest a correlation of the risk allele with higher expression levels 
of the 37-kDa variant, and lower expression levels of the 70-kDa variant. Hunt et al. (2008) 
showed that the risk allele correlates with lower levels of mRNA expression, consistent with 
our results for the full-length (70-kDa) protein. This may be a result of the design of the 
mRNA assay by Hunt et al. (2008), which identified only the full-length transcript. 
Given that little is known about the IL18RAP protein and its alternative splicing or 
functional isoforms, future studies should concentrate on their systematic characterisation in 
celiac disease-specific tissues, cells and inflammatory conditions. Indeed, alternative splicing 
of IL18RAP mRNA has been described in human and rat, coding for putative truncated 
proteins and soluble forms of the receptor (Andre et al. 2003, Fiszer et al. 2007). It would be 
interesting to examine whether the 37-kDa band is a biologically active isoform encoded by 
an alternatively spliced mRNA. This is of particular interest because its higher expression in 
the carriers of the risk allele is in line with the observed IFN -mediated Th1 response in celiac 
disease, which is not the case for the 70-kDa band nor the mRNA expression reported by 
Hunt et al. (2008). However, we cannot exclude novel alternative roles of IL18 signalling or 
putative coupling of IL18RAP with other cytokine receptor chains, thus forming new receptor 
complexes with unknown or even opposite functions to the IL18 pathway. Our knowledge 
about the pathology of IFN  and Th1 responses in celiac disease may also need a revision, as 
there is increasing evidence of Th17 cells involved in autoimmunity (Dardalhon et al. 2008). 
Immunohistochemical analysis of IL18RAP showed a wide variety of expression patterns 
and revealed no consistent differences between the untreated and treated celiac patients and 
the controls. Furthermore, no differences were observed between different IL18RAP 
genotypes. However, this analysis confirms that IL18RAP is expressed in the gut 
inflammatory mononuclear cells, thereby further supporting the involvement of this protein in 
celiac disease pathogenesis. 
Our study independently confirms the association results of Hunt et al. (2008) and 
supports IL18RAP as  a  novel  celiac  disease  risk  gene  in  the  Hungarian  population  and  
possibly also in the Finnish and Italian populations. The unclear nature of the risk genotype 
effects on protein levels highlights the need for future studies examining alternative splicing 
and receptor isoforms, as well as novel protein interactions or functions that will increase our 
understanding of this poorly studied gene in celiac disease pathogenesis. 
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3. Towards large-scale screening of risk-conferring HLA haplotypes 
for celiac disease 
Given that celiac disease is an important health problem because of its high prevalence, 
specific and non-specific morbidity and long-term complications (Mearin et  al. 2005, 
Romanos et al. 2008), early diagnosis is important, especially in high-risk groups such as 
first-degree relatives and individuals with type 1 diabetes, iron-deficiency anaemia or Down 
syndrome.  Although  the  presence  of  HLA  DQ2  or  DQ8  is  not  on  its  own  sufficient  for  
diagnosis, it can reveal the need for further serology tests and later a biopsy sampling in the 
risk groups. The absence of these molecules reduces the risk for the disease substantially. 
Testing for HLA risk haplotypes is routinely performed using methods which require 
several reactions, multiple steps such as amplification and hybridisation to a membrane, 
special software or expertise in analysing the results, and significant financial cost. To make 
HLA-typing more automated and less expensive, Monsuur et al. (2008) established a new 
approach using six tagging SNPs to predict whether an individual is heterozygous or 
homozygous for the DQ2.5, DQ2.2, DQ7 and DQ8 haplotypes. The tag SNP selection was 
based on genotype data collected in the classical HLA genes and more than 7500 common 
SNPs and insertion-deletion polymorphisms across the human MHC region (de Bakker et al. 
2006). Genotyping six SNPs is simple, fast and cost-effective compared to more classical 
techniques. In the Dutch, Spanish and Italian (Naples) populations, the sensitivity of this test 
was reported to be >0.991 and the specificity >0.996 (Monsuur et  al. 2008). Since LD 
patterns within the HLA region may differ between populations, our aim was to validate this 
method in four new populations.  
We genotyped the six HLA-tagging SNPs in the Finnish, Hungarian and Northern-Italian 
(Trieste) populations and compared the genotype with results from traditional HLA typing. 
Our findings showed that the sensitivity and specificity to detect the celiac disease risk alleles 
in the Finnish, Hungarian and Italian populations ranged from 95 to 100%. These results 
imply that this method can detect the haplotypes coding for DQ2 and DQ8 with high 
accuracy. In addition, the method is transferable to other Caucasian populations because it has 
now been validated in six different populations: Dutch, UK, Spanish, Finnish, Hungarian and 
Italian. 
Moreover, additional sets of controls from each population were also genotyped, as well 
as a case-control sampleset from Milan. Although no previous HLA-typing results were 
available from these samples, the HLA allele frequencies determined by the SNP method 
followed the known HLA allele frequencies in these populations. For instance, the haplotype 
frequencies of the Italian (Milan) set are comparable to the haplotype frequencies reported by 
Margaritte-Jeannin et al. (2004). This genotyping method enables the identification of 
individuals being homozygous or heterozygous for the risk haplotypes, allowing us to study 
the risk of celiac disease conferred by different HLA genotypes. Our data supports several 
previous findings of the dose effect of functional DQ2 heterodimers in risk of celiac disease 
(Ploski et al. 1993, Louka et al. 2002, Vader et al. 2003, Margaritte-Jeannin et al. 2004).  
Recently, the tagging SNP method was also shown to be useful for HLA testing in type 1 
diabetes and it should be useful in other HLA DR3-DQ2 or DR4-DQ8 associated diseases, 
such as systemic lupus erythematosus and rheumatoid arthritis (Barker et al. 2008). The 
method can also be used to exclude diagnosis of celiac disease in the absence of HLA DQ2 or 
DQ8 when screening high-risk groups (e.g. relatives of patients with celiac disease, and 
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patients with Down syndrome), which reduces the cost of follow-up serology screening 
(Csizmadia et  al. 2000, Kaukinen et  al. 2002, Mustalahti et  al. 2002a, Mearin et al. 2005, 
Romanos et al. 2008). 
The main benefits of the SNP typing method are significant reductions in cost and time, as 
well as its potential as a high-throughput assay. The TaqMan method used in this study is 
most cost-reducing when applied to the 96 or 384 sample formats, making this method highly 
suitable for large sample cohorts, typically those used in research and population screening 
studies.  
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Conclusions and future challenges 
In addition to the HLA DQ2 and DQ8 coding haplotypes, 14 susceptibility loci for celiac 
disease have now been identified through genome-wide linkage and association studies and 
their fine-mapping and follow-up studies. Many of these loci harbour more than one possible 
susceptibility gene, and only the role of DQ2 and DQ8 have been characterised in the 
pathogenesis of celiac disease. Several additional susceptibility genes have also been 
suggested by various candidate gene studies. The majority of the risk loci harbour genes with 
immunological functions, and many of these loci have also been associated with other 
autoimmune and inflammatory conditions. In particular, there appears to be multiple shared 
genetic risk factors for celiac disease, type 1 diabetes and inflammatory bowel disease, such 
as the IL2/21 and IL18RAP loci. There are also several reports of shared risk genes between 
celiac disease, rheumatoid arthritis and systemic lupus erythematosus, such as the TNFAIP3 
locus. 
The loci found by genome-wide linkage scans constitute large genetic regions, and the 
results of the fine-mapping studies have been somewhat contradictory. For example, MYO9B 
still constitutes a controversial candidate gene for celiac disease, although the original Dutch 
findings have been replicated in some other populations and similar pathologies. The lack of 
association with celiac disease in most replication studies may suggest a weaker effect size 
than  estimated  in  the  original  Dutch  study:  a  phenomenon often  seen  in  genetic  studies  and  
referred to as “a winner’s curse” (Ioannidis et  al. 2001).  More  powerful  study  designs  will  
probably be required to pinpoint the risk-conferring genes and variants in the CELIAC2, 
CELIAC3, and CELIAC4 regions. Allelic heterogeneity and differences in the allele 
frequencies and LD patterns between populations are also possible explanations for the weak 
associations found and the discrepancies between different studies. The lack of association to 
these regions in the whole-genome association study by van Heel et al. (2007) might reflect 
insufficient power to detect associations in these regions, which may also have been a 
problem in previous fine-mapping studies.  
Genome-wide association studies have been successful in detecting common risk variants 
(MAF > 1%) with modest effect sizes (OR 1.1 – 1.5). Even though several novel risk genes 
for  complex  diseases  have  been  found through these  scans,  the  effect  of  luck  to  detect  risk  
variants with small effect sizes in previous genome-wide association studies should perhaps 
not be underestimated. It has been estimated that with 2000 cases and 3000 controls, the 
power to detect disease risk variants with minor allele frequencies above 5% is only 43% for 
alleles  with  a  relative  risk  of  1.3  for  a  p-value  threshold  of  5   10-7 in a genome-wide 
association study published by the Wellcome Trust Case Control Consortium (2007). This 
implies that increasing sample sizes in genome-wide association scans should lead to 
substantial increases in the number of identified associations. This kind of studies with high 
statistical power to detect risk genes with small effect sizes will also be needed in the future 
for celiac disease, and they will most likely require multiple populations. There are already 
some examples of such meta-analyses of genome-wide association data, utilising thousands of 
cases and controls from several populations, leading to novel risk gene findings (Zeggini et al. 
2008, Houlston et al. 2008, Cooper et al. 2008, Aulchenko et al. 2009).  
The findings from genome-wide association studies have provided clues to understanding 
the architecture of the genetic risk of complex diseases in general. In addition to the 
identification of numerous novel susceptibility loci and new biological associations, these 
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studies have revealed future challenges. A substantial proportion of the detected risk variants 
are located in non-coding and intergenic regions (Hindorff et al. 2009) 
(http://www.genome.gov/26525384), calling for studies investigating the functions of non-
coding variants. The associated SNPs are perhaps rarely the causal risk variants and 
techniques such as sequencing may be needed to identify the true functional risk variants. In 
celiac disease, all risk loci highlighted in the genome-wide association study and its follow-
ups are located in intronic and intergenic regions within blocks of strong LD. The IL18RAP 
locus is an example of a locus where strong association is found and confirmed in multiple 
populations, but confirming the functions of the genes in pathogenesis requires further efforts. 
To date, variants identified by genome-wide association studies only explain a small 
fraction of the overall genetic risk for disease, and a large portion of the genetic variance still 
remains to be found (Altshuler et  al. 2008). For example, it has been estimated in celiac 
disease that the non-HLA risk SNPs found in the genome-wide association study and its 
follow-up studies account for only 3-4% of the heritability; the HLA region accounts for an 
additional 30% (Hunt and van Heel 2009). There is also evidence that the universe of rare 
structural changes contributing to each disease may be as extensive and diverse as that of 
common SNPs (Altshuler et al. 2008). Such variants are beyond the reach of current genome-
wide association technologies. In addition, gene-gene interactions should be investigated 
further because they may have substantial effects on disease risk, despite the risk conferred by 
individual genes being small. 
Functional candidate gene studies have suggested a number of susceptibility genes for 
celiac disease, but their role in disease risk still remains to be confirmed. Multiple studies 
have shown modest associations, often implying an under-powered study or perhaps even 
false-positive or false-negative findings. The findings of these studies often fail to be 
consistently replicated (Hirschhorn et al. 2002, Gorroochurn et al. 2007). Indeed, as we have 
learnt from genome-wide association scans, the effect sizes of the common risk-conferring 
variants  for  complex  diseases  are  modest.  Perhaps  the  risk  effect  has  been  estimated  to  be  
larger than it really is, leading to ambiguous and non-replicated/non-replicable association 
results. Genome-wide association studies may be making candidate gene studies a less 
popular approach to study disease-gene correlations, but there is still a niche for well-
designed and well-powered candidate gene studies as well, if an interesting gene is proposed. 
Some loci or haplotypes may be missed in genome-wide studies, if none of the variants are in 
LD with the SNPs used in the genotyping arrays, or else because of allelic heterogeneity 
(Altshuler et al. 2008).  
Finally, one may ask whether the high number of susceptibility genes, each only 
marginally increasing disease risk, will have clinical consequences. The novel association 
findings give us valuable information on the biology and molecular pathways underlying 
disease pathogenesis, thereby providing us with tools to create novel diagnostics and 
therapeutics in the future. Predictive gene testing could also be performed if modest risk 
effects can help guide clinical decision-making and increase knowledge about the efficiency 
of clinical intervention, and if there are means for preventive interventions. 
To date, the HLA locus remains the strongest single risk locus for celiac disease, with the 
other identified loci having risk effects of less than 2-fold. Only genotyping of HLA DQ 
haplotypes is currently used to exclude the diagnosis of celiac disease, and a new tool for 
screening populations or other large samplesets has now been developed (Monsuur et al. 
2008). We are beginning to understand more about the genetics of celiac disease, as well as 
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the nature and function of susceptibility genes and their interactions with each other and their 
environment. This new information will aid our understanding of the pathogenesis of celiac 
disease, hopefully leading to better patient outcomes. New advancements in the field of 
complex disease genetics can be expected in the near future as large-scale genome-wide 
association scans and high-throughput sequencing will take place. Such approaches are 
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